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 Alzheimer’s disease (AD) is the most common form of dementia, affecting 5.8 
million people in the United States alone. Currently, there are no disease-modifying 
treatments for AD, and the cause of the disease is unclear. With the increasing 
number of cases and the lack of treatment options, AD is a growing public health 
crisis. As such, there is a push for investigation of novel pathological mediators to 
inform new therapeutic approaches.  
Cardiovascular disease and associated cardiovascular risk factors (CVRFs) 
are linked to a significantly increased risk for developing AD, but the mechanisms 
whereby these risk factors contribute to the pathological processes in the AD brain 
have not been defined. Because CVRFs affect vascular function, a dysfunctional 
cerebrovasculature could be an important driver of CVRF-induced injury in the AD 
brain. Furthermore, the cerebrovasculature is both a source of, and target for, 
inflammatory mediators, indicating that a dysfunctional cerebrovasculature likely 
participates in the robust neuroinflammatory response found in the AD brain.  
In particular, type II diabetes mellitus (T2D) is associated with a more than 
doubled risk for developing AD. Hyperglycemia-induced endothelial activation and 
related inflammatory processes are key pathological features in T2D. Here, we 
investigate vascular dysfunction and neuroinflammation in diabetes-like conditions in 
vitro. Results show that brain endothelial cells treated with hyperglycemia and 
hypoxia in vitro become injured and release inflammatory mediators. This endothelial 
injury activates a pro-inflammatory microglia phenotype in a co-culture system, 
characterized by significantly increased production of inflammatory cytokines and 
nitric oxide (NO), and increased expression of microglia activation markers. These 
microglia changes mimic those found in the AD brain, highlighting that endothelial 
damage and dysfunction may be a driver of neuroinflammatory activation in AD.  
 
 
 Mutations to the lipid transport protein apolipoprotein E (ApoE) have been 
identified as the strongest genetic risk factor for sporadic or late-onset AD, with the 
E4 allele representing an increased risk and the rare E2 having a reduced risk 
compared to the primary E3 form. While the risk is well documented, the mechanisms 
responsible for this risk are not well understood. We examined the effects of ApoE 
isoforms on markers related to vascular function, neuroinflammation, and 
neurotoxicity using in vitro and in vivo models. In vitro, the ApoE4 isoform induces 
pro-inflammatory activation of both microglia and astrocytes, as well as enhanced 
neurotoxicity. On the other hand, ApoE2 promotes neuronal survival through both 
direct and indirect actions on neurons. Using an in vivo mouse model, we show that 
ApoE4 promotes blood-brain barrier dysfunction and neuroinflammation, 
characterized by loss of tight junction proteins, and increased oxidative stress and 
pro-inflammatory cytokines. Additionally, our results indicate that the ApoE4 isoform 
promotes an inflammatory-oxidative state to a greater extent in female mice than in 
males.  
 Recent research indicates that components of the coagulation cascade may 
act as mediators of vascular dysfunction and inflammation in both cardiovascular 
disease and in AD. One such protein is the serine protease thrombin, which is 
elevated in the AD brain. Here, we present an extensive literature review, which 
posits that thrombin acts on endothelial cells of the blood-brain barrier, microglia, 
astrocytes, and neurons in a manner that promotes vascular activation, inflammation, 
and neurodegeneration. Additional evidence suggests that pharmacologically 
targeting thrombin may be an effective treatment strategy for targeting multiple points 
of AD pathology. We investigated thrombin’s role as a pathological mediator and 
potential therapeutic target and show that treatment of a tau-based AD mouse model 
in vivo with the direct thrombin inhibitor dabigatran produced significantly reduced 
 
 
oxidative stress and tau phosphorylation, and promoted cell survival and synaptic 
function.  
 Taken together, our results suggest vascular activation and related 
neuroinflammation as possible convergence points whereby CVRFs promote AD-
related pathological processes. Furthermore, we highlight shared pathological 
mediators that may represent novel therapeutic targets for the treatment of multiple 
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JUSTIFICATION OF RESEARCH 
 
Alzheimer’s disease 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder 
characterized by progressive loss of memory and other cognitive functions. In 2019, 
there were an estimated 5.8 million Americans with AD, costing approximately 290 
billion in health care [1]. The causes of AD are unclear, but increased risk for 
development has been linked with a number of factors, including lifestyle, genetics, 
and environment [2]. The AD brain demonstrates profound neuron death, particularly 
in the hippocampus, as well as pathological protein aggregation in the form of 
amyloid plaques and neurofibrillary tangles, made up of aggregated amyloid-β (Aβ) 
and hyperphosphorylated tau, respectively [3]. The AD research field has largely 
focused on the amyloid hypothesis, postulating that disease progression is caused by 
pathological accumulation of A oligomers and/or deposits of Aβ into plaques. The 
importance of this hypothesized role has recently been called into question following 
multiple clinical trial failures using agents that targeted A generation, aggregation, or 
clearance [4-8].  
Recent research has expanded our understanding of AD as a complex, 
multifactorial disorder with pathological roles implicated for neuroinflammation, 
vascular dysregulation, protein aggregation, mitochondrial dysfunction, and other 
non-amyloid based factors [7, 9-11]. The growing number of AD cases, along with the 
lack of successful treatment options, make AD a growing public health crisis. As such, 
the investigation of novel pathological mediators is needed in order to inform new 
therapeutic approaches that target multiple-disease related factors.   
Cardiovascular disease and AD 






 There is an ever-growing literature documenting the relationship between 
cardiovascular risk factors (CVRFs) and AD. The risk for developing AD significantly 
increases in the presence of a number of CVRFs, including hypertension, 
hypercholesterolemia, hyperhomocysteinemia, possession of an apolipoprotein E4 
(ApoE4) allele, diabetes, and atherosclerosis [12-16]. CVRFs in early adulthood 
through midlife are associated with significantly worsened cognitive performance, 
including poor cognitive function, impaired executive function, and dementia later in 
life [17-19]. Furthermore, epidemiological evidence indicates a connection between 
midlife blood pressure and cholesterol levels and late-life AD [20]. Diabetes in 
particular is strongly linked to Alzheimer’s, with type II diabetes mellitus (T2D) more 
than doubling the risk for developing AD [21-23].  
Vascular dysfunction is present in cardiovascular disease and Alzheimer’s 
Vascular dysfunction occurs as the result of non-adaptive alterations in the 
phenotype of vascular endothelial cells in response to disease-related stimuli [24, 25]. 
Alterations in endothelial cell metabolism and imbalances in protein phosphorylation 
are characteristic of cardiovascular diseases, such as diabetes, hypertension, and 
atherosclerosis [25, 26]. Vascular dysfunction results in impaired endothelial nitric 
oxide synthase (eNOS) function, significantly increased oxidative stress and 
inflammation, abnormal angiogenesis, and impaired endothelial cell repair [24, 27, 
28]. This dysfunction often includes endothelial activation, in which endothelial cells 
take on a highly synthetic, pro-inflammatory, and pro-coagulant phenotype.  
Evidence indicates that vascular dysfunction is present in the pathogenesis of 
AD. Findings from both animal and human studies suggest that cerebrovascular 
dysfunction precedes neurodegenerative changes in AD [29]. Disruption of the blood-






mild cognitive impairment (MCI) and AD patients, often co-localized to areas of 
amyloid plaque build-up [30, 31]. Moreover, BBB permeability is correlated with AD 
progression in both animal and human-based studies [32, 33]. Taken together, these 
findings indicate a role for vascular dysfunction in the pathological progression of AD. 
Diabetes-related hyperglycemia as a mediator of vascular dysfunction and 
inflammation 
T2D is associated with a substantially increased risk for developing AD, a 
relationship that is not fully understood [21-23]. Diabetes-related pathology is 
primarily the result of hyperglycemia-induced endothelial dysfunction throughout the 
body. There are several mechanisms suggested for vascular complications in 
response to hyperglycemia, with the primary factor implicated to be increased 
production of superoxide by the mitochondrial electron-transport chain [34-36]. 
Additionally, hyperglycemic conditions lead to significantly impaired eNOS function 
and NADPH oxidase (NOX) activation, producing high levels of oxidative stress [26].  
Hyperglycemia in T2D is associated with BBB dysfunction, leading to 
decreased expression of tight junction proteins and increased secretion of 
inflammatory mediators. This further induces morphological changes to endothelial 
cells and significantly increases BBB permeability [37]. Diabetes-associated BBB 
dysfunction produces neuroinflammation, neuronal dysfunction, and protein 
aggregation [38]. Mouse models of diabetes exhibit significant BBB damage, memory 
deficits, alterations to protein expression by the cerebrovascular system, and 
increased activation of microglia [39, 40]. In vitro, high glucose treatment of a BBB 
model produced significantly decreased expression of tight junction proteins and 






found in Alzheimer’s disease [29-31], indicating that the BBB may be one key area in 
investigating the relationship between diabetes and the risk for AD.   
Hyperglycemia-related BBB damage and dysfunction leads to significant 
increases in markers of neuroinflammation, including increased reactive oxygen 
species (ROS) and inflammatory cytokines [37, 38, 42]. These neuroinflammatory 
effects may, in part, be consequences of endothelial cell-microglia cross talk. 
Microglia can induce disruptions in tight junctions, stimulate angiogenesis, and induce 
endothelial cell migration [43]. Less is known about endothelial cell effects on 
microglia, though endothelial cells are known to release a number of signaling 
molecules that influence microglia phenotype, including interleukin (IL)-1, IL-6, matrix 
metalloproteinases (MMPs), and thrombin [44-48]. Importantly, there are parallels 
found between inflammation in T2D and AD. Both processes exhibit common 
inflammatory mediators, particularly cytokines, including tumor necrosis factor-α 
(TNF-α) and IL-6. Additionally, the inflammatory response in both T2D and AD is 
largely driven by macrophages, in the periphery and brain, respectively [49].  
Apolipoprotein E as a shared risk factor in cardiovascular disease and Alzheimer’s 
disease 
The most significant genetic risk factor for late-onset AD is an allele variant of 
apolipoprotein E (ApoE), a protein involved in cholesterol transport [50]. The ApoE 
gene has three polymorphic alleles in humans, E2, E3, and E4. The E4 variant is 
associated with cardiovascular disease in the periphery, particularly atherosclerosis, 
further highlighting the connection between cardiovascular disease and AD [51, 52]. 
Population based studies show that just one copy of the E4 allele is associated with 
an almost 50% increase in prevalence of AD and lower age of onset for the disease, 






by approximately 40% [53]. Evidence for ApoE4’s association with AD is supported 
by the findings that ApoE4 is related to impaired cognition in midlife and higher 
conversion of mild cognitive impairment (MCI) to AD [54-56]. Additionally, the 
presence of ApoE4 significantly increases the likelihood that cardiovascular disease 
and Alzheimer’s will co-occur. For example, carrying the ApoE4 more than doubles 
the likelihood that individuals with T2D will develop AD or mixed dementia [52, 57, 
58].  
 One mechanism whereby ApoE contributes to atherosclerosis and AD is 
through effects on vascular function. ApoE4 carriers exhibit altered cerebral blood 
flow (CBF) compared to ApoE3 starting in young adulthood and continuing through 
late adulthood, likely the result of impaired neurovascular coupling [51, 59]. ApoE4 
carriers show greater decline in CBF during late adulthood [60]. ApoE4 individuals 
have an 8-10.5% reduction in cerebral glucose metabolism, starting in early 
adulthood [59, 61]. In mouse models, ApoE4 modulates cerebrovascular integrity and 
significantly increases BBB permeability via alterations in signaling at the 
neurovascular unit [62]. In an in vitro model of the BBB, ApoE4 was associated with 
significantly reduced tight junction integrity and increased barrier leakiness compared 
to ApoE3 [63].   
Newer findings have presented a novel, alternative role for ApoE4 as a 
mediator of the brain’s inflammatory response. ApoE4 is associated with changes in 
inflammatory markers in both in vivo and in vitro models of cardiovascular disease 
and AD [64]. ApoE signaling has been linked to the conversion of microglia to disease 
associated microglia (DAM) in the AD brain, and ApoE is a ligand for the triggering 
receptor expressed on myeloid cells 2 (TREM2) receptor [65, 66]. Microglia isolated 






including significantly increased production of TNF-α, IL-6, and reactive nitrogen 
species (RNS) [67, 68]. ApoE4 is also associated with increased secretion of 
inflammatory factors, such as IL-1β and NO, in both human and rat macrophages in 
vitro [69-71]. More recent research using mass spectrometry analysis of human brain 
tissue further supports a role for ApoE in modulating the expression of inflammation-
related factors. In analyzing brain tissue expressing e2/e3, e3/e3, or e4/e4, 
researchers found that expression of proteins related to the regulation of 
inflammatory response was significantly correlated with ApoE genotype [72]. The 
study of ApoE4 in relation to vascular function and inflammation represents a shift 
from previous focus on ApoE4’s lipid transport functions, including its role in 
metabolism and deposition of Aβ [64]. 
Thrombin as a pathological mediator of cardiovascular disease and Alzheimer’s 
disease 
A number of mediators implicated in the pathological progression of both 
cardiovascular disease and inflammation may also play a role in AD. One such factor 
is the serine protease thrombin, a coagulation protein that is elevated in both 
cardiovascular disease and AD [73, 74]. Thrombin levels are significantly elevated 
around atherosclerotic plaques, and increases in thrombin are correlated with 
atherosclerosis disease severity [75]. Thrombin activity is significantly elevated in 
T2D, and its activity is linked to endothelial activation and increased production of 
reactive oxygen species (ROS) [76, 77].  
Thrombin has been implicated as a pathological mediator in Alzheimer’s 
disease. Instances of traumatic brain injury (TBI), where neurons are exposed to high 
levels of thrombin, are associated with a 1.2 to 2-fold increased risk for AD [78, 79]. 






reduced levels of the thrombin inhibitor protease nexin-1 [74, 80, 81]. Thrombin 
expression is approximately doubled in AD patient-derived microvessels compared to 
controls, and brain endothelial cells isolated from AD patients synthesize their own 
thrombin in vitro [82, 83]. Animal models of AD exhibit elevated levels of thrombin in 
vivo [84]. Thrombin has also been associated with typical hallmarks of AD pathology. 
Rats treated with thrombin in vivo exhibit impaired reference and spatial memory [85]. 
Thrombin accumulates in neurofibrillary tangles and is related to rapid tau 
aggregation [86, 87]. Thrombin is implicated in altered processing and secretion of 
amyloid precursor protein (APP) [88, 89], and thrombin cleavage of ApoE4 results in 
a neurotoxic fragment [90].  
Thrombin acts as a cell signaling mediator through its activation of protease 
activated receptors (PARs) [91, 92]. Thrombin signaling in the periphery has been 
linked to significantly increased pro-inflammatory cytokines and ROS production [73, 
76, 93, 94]. PARs are expressed throughout the central nervous system (CNS), 
including by neurons, astrocytes, microglia, and neurons, and thrombin signaling has 
a number of effects on the brain [95, 96]. Thrombin has significant, deleterious effects 
on endothelial cells of the BBB, inducing increased leukocyte adhesion and 
decreased tight junction formation, as well as increased release of inflammatory 
factors and ROS [45, 82, 97-101]. Thrombin acts directly on both microglia and 
astrocytes to initiate a pro-inflammatory phenotype [46, 47, 102, 103] [85, 104-106]. 
High doses of thrombin are neurotoxic, indirectly through changes to the surrounding 
environment, and directly through alterations in the neuronal cell cycle [46, 102, 107-
109].  
Further evidence for the role of thrombin comes from the finding that fibrin, like 






neuroinflammation in neurodegenerative diseases, including AD [110, 111]. Fibrin is 
the result of thrombin cleavage of fibrinogen, and is therefore a product of increased 
thrombin activity [112]. Fibrin(ogen) has been shown to have proinflammatory effects 
in the CNS, including the activation of glia and disruption of the BBB [111]. Fibrinogen 
deposition was found in AD brains, indicative of BBB leakiness. Additionally, in both 
human AD and a rat model, fibrinogen was associated with areas of Aβ deposition, 
and enhanced the pro-inflammatory and vascular disrupting effects of Aβ1-42 [113]. 
Fibrinogen activates microglia in a CD11b-dependent manner [114], and fibrinogen-
CD11b binding was found to promote axonal degeneration, spine elimination, and 
cognitive impairment in a mouse model of AD [115]. 
 Thrombin and fibrin are not the only components of the coagulation cascade 
found to act as pathological mediators in AD [116]. For example, the factor XII-
initiated contact system is activated in AD patients and mice, and depletion of factor 
XII ameliorates brain pathology and cognitive impairment in an AD mouse model 
[117, 118]. Additionally, anti-coagulant components of the cascade, including 
activated protein C (APC), have been found to have anti-inflammatory and protective 
effects in AD models [119]. The finding that fibrin and other downstream components 
of the coagulation cascade act as disease mediators further highlights the potential 
role for thrombin in the development and progression of AD, through both direct and 
indirect effects in the brain.  
Neuroinflammation in Alzheimer’s disease 
Neuroinflammation is a key component of disease pathology in a number of 
neurodegenerative diseases, including AD [3, 120, 121]. Pro-inflammatory cytokines 
and chemokines are significantly elevated in the brain and serum of AD patients 






chemoattractant protein-1 (MCP-1), TNF-α, IL-1β, and IL-6 [121-123]. 
Neuroinflammation appears early in disease time course, suggesting an important 
pathological role in the development of AD, and a potential target for early therapeutic 
intervention [121]. Additionally, a number of key AD risk genes are related to the 
function of the innate immune system, including complement receptor 1(CR1), CD33, 
and TREM2 [124-127].  
Neuroinflammation in Alzheimer’s is primarily driven by the glial cells of the 
brain, particularly microglia and astrocytes [128]. Activated microglia and astrocytes 
have been found localized around Aβ plaques in the AD brain [128-131]. Both cell 
types are responsible for the secretion of inflammatory cytokines and mediators, 
including NO and ROS, COX-2, TNF-α, IL-1β, and IL-6 [120, 128, 132-134]. While 
both astrocytes and microglia are involved in the inflammatory response, microglia 
are the primary drivers of inflammation in the brain [134]. 
Microglia in Alzheimer’s disease 
 Microglia are the resident immune cells of the brain, and are key mediators of 
the neuroinflammatory response. These cells become activated in response to 
pathogen invasion or tissue damage and promote an inflammatory response. This 
inflammatory response is intended as an adaptive response, but chronic exposure to 
inflammatory mediators produced by microglia can activate apoptosis and necrosis, 
resulting in neurodegeneration [135]. Previously, microglia were recognized as having 
two activation states, the M1 pro-inflammatory phenotype, and the M2 “quiescent” 
phenotype. Newer evidence suggests this is an oversimplification, pointing instead to 
a range of microglia phenotypes that may be present during health and disease [120]. 
More recent literature has highlighted a “disease-associated microglia” (DAM) 






mouse brains [136]. This microglial phenotype has also been termed 
“neurodegenerative microglia” (MGnD) [65]. DAMs show downregulation of 
homeostatic microglia genes (ex. p2ry12/p2ry13, cx3cr1, tmem119) and upregulation 
of pro-inflammatory and AD-associated factors (ex. apoe, tyrobp, itgax, clec7a, trem2) 
[65, 136]. The conversion from homeostatic microglia to DAM is purported to occur in 
a two-step process: the first step is TREM2-independent and includes the down-
regulation of microglia checkpoints, while the second is TREM2-dependent and 
causes the activation of lipid metabolism and phagocytic pathway genes [136]. 
Further study has indicated a possible subset of DAM that are pro-inflammatory [137, 
138], but additional investigation is needed to fully understand the significance of 
DAM to AD pathology.   
Dissertation Objective 
 The following dissertation proposal will explore new strategies to examine the 
role of cardiovascular disease-related risk factors and inflammation in Alzheimer-
related pathology. Major outcomes of the proposed experiments will provide new 
insights into the relationship between cardiovascular disease, vascular activation, 
inflammation, and Alzheimer’s pathology, as well as inform novel therapeutic 
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A strong link between Type 2 Diabetes Mellitus (T2D) and Alzheimer’s disease (AD) 
has been identified, but the reason behind this increased risk is not well understood. 
Hyperglycemia damages brain endothelial cells, and the cerebrovasculature is a key 
component of the brain’s inflammatory response in disease. Neuroinflammation, 
primarily regulated by microglia, is a key aspect of AD pathology. The goal of this 
study was to assess the effect that human brain microvascular endothelial cell 
(HBMVEC) injury in vitro by stressors related to diabetes would have on the activation 
state of microglia. HBMVECs were treated with high-glucose with or without hypoxia. 
HBMVEC-conditioned media was then used to treat BV-2 microglia. Alterations in 
microglia phenotype were assessed through measurement of Nitric Oxide (NO) 
production, cytokine production, and changes in expression of known microglia 
markers. HBMVEC injury through glucose and hypoxia induced changes in BV-2 
phenotype, including increased production of NO and TNFα, as well as altered 
expression of a number of homeostatic and “activated” microglia markers, including 
CD11c, CLEC7A, and P2Y12. Additionally, BV-2 exhibited altered phagocytic ability 
following treatment with HBVMEC-conditioned media. Together, these findings 
suggest that diabetes-like damage to the brain endothelial cells may help to initiate a 










Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by 
progressive loss of cognitive function, leading to dementia and death. The staggering 
number of AD cases, 6 million currently in the US and projected to increase to over 
13 million by 2050 [1], underlies the urgency to better understand and treat this 
devastating disorder. It has become clear in recent years that AD is a complex, 
multifactorial disorder where disparate processes likely converge to produce neuronal 
injury. Many studies have shown that cardiovascular risk factors (CVRFs), such as 
hypertension, atherosclerosis, and diabetes, are important risk factors for the 
development of AD [2-6]. Diabetes especially has been strongly linked with AD, as 
individuals with type 2 diabetes mellitus (T2D) have a greater than 50% increase in 
their risk for developing AD [7-9]. Though the mechanisms whereby diabetes 
contributes to pathological processes in the AD brain have not been delineated, in the 
periphery diabetes and other CVRFs are potent drivers of inflammation [10]. Because 
neuroinflammation is a consistent feature of AD, and other neurodegenerative 
diseases, inflammation could be a key target for the effects of diabetes in the brain. 
Inflammation is, by definition, vascularized tissue response to injury, and as 
such, endothelial cells are key players in the development of inflammation in the brain 
[11]. Chronic inflammation is tightly linked to diseases associated with endothelial 
dysfunction. Sustained hyperglycemia, a pathognomonic feature of diabetes, leads to 
endothelial cell dysfunction and the activation of several pathways including 
stimulation of the polyol and glucosamine pathways, activation of protein kinase C, 
and formation of advanced glycation end products (AGEs) [12]. Furthermore, high 
levels of glucose in diabetes contribute to endothelial injury by increased expression 






vascular complications in diabetes is linked to mitochondrial superoxide 
overproduction in the endothelium [13-15].  
Individuals with diabetes are at increased risk for a number of secondary CNS 
conditions, including stroke and cognitive dysfunction [16-18]. While diabetes 
negatively impacts multiple processes and cells in the brain, microvascular 
endothelial cells are the cell type at the blood-brain interface that are most directly 
exposed to the deleterious effects of high glucose levels. In this regard, numerous 
studies have documented diabetes-induced alterations of blood-brain barrier (BBB) 
function. Both in vitro models utilizing high-glucose conditions and in vivo 
experiments with diabetic animals have shown compromised BBB integrity. 
Significantly increased BBB permeability, as well as morphologic modifications of the 
microvasculature, including excess collagen deposition, accumulation of lipid 
peroxidation byproducts, and degeneration of endothelial cells, have been 
documented [18]. Glucose-induced increase in BBB permeability is mediated in part 
by partial loss of junctional proteins ZO-1, occludin, and claudin-5, and increased 
NADPH oxidase (NOX) activity [18-20]. Finally, gene expression profiling of isolated 
microvessels from diabetic animals shows increases in several inflammatory proteins, 
including tumor necrosis factor-α (TNFα) and matrix metalloproteinase (MMP)-9 [21].  
There is robust elevation in inflammatory mediators in the AD cerebral 
microcirculation. AD brain endothelial cells express high levels of inflammatory 
adhesion molecules, such as monocyte chemoattractant protein-1 (MCP-1), 
intercellular adhesion molecule-1 (ICAM-1), and cationic antimicrobial protein 37 kDa 
(CAP37) [22]. Additionally, AD brain microvessels release significantly higher levels of 
nitric oxide (NO), thrombin, TNFα, transforming growth factor-β (TGF-β), interleukin 






regards to AD pathology, the cerebral microvasculature is also a participant in a cycle 
of events where inflammation precedes Aβ deposition, and Aβ in turn promotes 
release of inflammatory mediators. In this regard, exposure of brain endothelial cells 
to Aβ has been shown to evoke an array of pro-inflammatory responses. Cultured 
brain endothelial cells exposed to Aβ1-40 exhibit increased expression of MCP-1, IL-
1β, and IL-6 [22]. Therefore, the cerebromicrocirculation serves as both a source of, 
and a target for, inflammatory proteins. 
The inflamed endothelium is a highly synthetic interface that produces 
numerous bioactive factors. We have previously shown that microvessels isolated 
from the AD brain are inflamed and secrete proteins that have direct neurotoxic 
effects on neurons [26]. It is likely that endothelial-derived mediators will also have 
critical effects on neighboring microglia, as many of the inflammatory proteins 
released by activated brain endothelial cells (such as IL-1β and thrombin) induce pro-
inflammatory responses in microglia. Although the possible effects of injured brain 
endothelial cells on microglia have not been explored, microglia are part of the 
neurovascular unit (NVU). The NVU is defined as a metabolic unit consisting of brain 
endothelial cells, neurons, astrocytes, microglia, pericytes, vascular smooth muscle 
cells, and oligodendrocytes [27]. The functional interaction of NVU cells through 
bidirectional cell-cell signaling is critical for maintaining cerebral blood flow and 
regulating physiologic processes in the central nervous system (CNS). Microglia 
activated by treatment with LPS can induce alterations in brain endothelial cell 
morphology and function [28], but less is known about endothelial cell effects on 
microglia. 
Microglia, the brain’s resident immune cells, are key drivers of the 






Once described as existing in a quiescent or resting state, microglia are dynamic cells 
that are constantly surveying their microenvironment for injury-inducing mediators 
[31]. Microglia were previously regarded as having either a pro-inflammatory (M1) or 
resting (M2) phenotype, but more recent research views microglial activation patterns 
as more complicated, with microglia assuming a diversity of phenotypes in response 
to noxious extracellular signal [32, 33]. Microglia play a pivotal role in the 
maintenance of brain homeostasis, but those homeostatic functions are lost in 
neurodegenerative disorders. Multiple groups have identified a disease associated 
microglia (DAM) or microglial neurodegenerative phenotype (MGnD), which is present 
in AD [34, 35]. These DAM show downregulation of homeostatic microglia genes, 
including p2ry12/p2ry13 and tmem119, and upregulation of pro-inflammatory and AD-
associated factors, including apoe, clec7a, and cd11c. Additionally, proliferation and 
activation of microglia in the brain, concentrated around amyloid plaques, is a 
prominent feature of AD [36, 37]. Furthermore, a number of recently identified AD-risk 
genes are related to regulation of microglia and the innate immune system, including 
complement receptor 1 (CR1) and triggering receptor expressed on myeloid cells 2 
(TREM2) [38-41]. These findings suggest that shifts in microglia function and 
phenotype are a key part of the pathological development of AD.  
The goal of this study was to assess the effect that human brain microvascular 
endothelial cell (HBMVEC) injury in vitro by stressors related to diabetes would have 
on the activation state of microglia. HBMVECs exposed to high-glucose functions as 
an in vitro model of the hyperglycemia found in diabetes. Additionally, diabetes is 
related to a number of secondary complications, including significantly increased risk 
of cerebral ischemia, with some evidence suggesting that hyperglycemia-induced 






Therefore, hypoxia was implemented as an additional stressor to induce endothelial 
cell injury in this in vitro model. We hypothesize that diabetes-related endothelial cell 








Cell culture and other reagents  
Human brain microvascular endothelial cells (HBMVECs- ACBRI 376) and 
complete medium with recombinant growth factors (4Z0-500) were purchased from 
Cell Systems (Kirkland, WA, USA). Murine immortalized microglia (BV-2) were kindly 
provided by Dr. Navindra Seeram (University of Rhode Island, Kingston, RI, USA). 
Low-glucose Dulbecco’s Modified Eagle Medium (DMEM), cell culture grade D-
glucose, antibiotic/antimycotic (Ab/Am), fetal bovine serum (FBS), and Bovine Serum 
Albumin (BSA) were purchased from Sigma Aldrich (St. Louis, MO, USA).  
Culture and treatment of HBMVECs and BV-2 
HBMVECs were maintained in culture in complete medium in accordance with 
protocols described by Cell Systems. Cells were maintained at 37°C in 5% CO2 in 
complete medium. Media was switched to low glucose (5mM) DMEM with 1% bovine 
serum albumin for treatments. HBMVECs were incubated with low glucose (5mM) or 
high glucose (30mM) treatment media for 6 hr. Cells were maintained in normoxia for 
the full 6 hr, or were exposed to hypoxic (1% O2) conditions for the final 1 hr of 
treatment. Following treatment, conditioned media were collected and centrifuged 
briefly at 1,000 x g in sterile conditions to pellet debris, and used for subsequent 
treatment of BV-2.  
BV2 were maintained at 37°C in 5% CO2 in low glucose (5mM) DMEM with 
10% FBS, 1% Ab/AM, and 250 nM L-glutamine added. HBMVEC-conditioned media 
was used to treat BV-2 for 24 hr. Control groups were treated with low glucose or 







Cellular damage of HBMVECs was assessed by measuring lactate 
dehydrogenase (LDH) release in the conditioned medium. Following treatment, 
supernatant was transferred to a clear 96-well plate and total LDH was assessed 
using the cytotoxicity detection kit (Millipore Sigma, Burlington, MA, USA). 
Absorbance values were read at 490nm following incubation with supplied 
chromogenic dye and catalyst using a Synergy HTX multi-mode reader (Biotek 
Instruments, Winooski, VT, USA). 
Detection of Reactive Oxygen Species (ROS) 
The production of reactive oxygen species (ROS) in HBMVECs was 
determined by a fluorescent probe (DCF-DA) using a previously described method 
with modification (Ma et al., 2017). HBMVECs were seeded in a black-walled, clear-
bottom 96-well plate at a density of 10,000 cells per well (100,000 cells per mL) and 
allowed to grow for 36 hr. Cells were then treated as previously described with high 
glucose with or without hypoxia for 6 hr in serum-free conditions. Following the 6-hr 
treatment, DCF-DA (10µM) was added to each well and incubated at 37°C in the dark 
for 25 min. Cells were washed 3 times with phosphate buffered saline (PBS). The 
fluorescence signal of each well was measured at 495nm (excitation) and 529nm 
(emission) using a SpectraMax M2 plate reader (Molecular Devices, Sunnyvale, CA, 
USA).  
Griess Assay 
The production of nitric oxide species (NOS) was determined using the Griess 
reagent system. BV-2 were grown in clear 24-well plates at 100,000 cells/mL. 
Following treatment with HBMVEC-conditioned media for 24 hr, culture media was 






reagent kit (Promega, Fitchburg, WI, USA). Absorbance values were read at 535nm 
using a Synergy HTX multi-mode reader (Biotek Instruments, Winooski, VT, USA). 
Western Blot 
Following treatments, cells were rinsed in ice-cold PBS and lysed in 10mM 
Tris-HCl, 150mM NaCl buffer containing protease inhibitors. Lysates were mixed with 
40% 4x Sample Buffer (4x Laemmli Sample Buffer (BioRad, Hercules, CA, USA) with 
10% 2-mercaptoethonal) and heated to 100°C for 10 min. Samples were resolved by 
SDS-PAGE on 4-20% Novex gradient gels (Invitrogen, CA) transferred to 
nitrocellulose membranes (iBlot, Invitrogen, Carlsbad, CA, USA). Membranes were 
blocked in 5% BSA in Tris buffered saline (TBS) containing 0.05% Tween-20. Primary 
antibodies for this study include iNOS (Abcam, MA; 1:250), TREM2 (Novus 
Biologicals, CO, 1:500), Iba1 (GeneTex, CA, 1:1,000), CLEC7A (Novus Biolgoicals, 
CO, 1:500), P2RY12 (Novus Biologicals, CO, 1:500), CD11c (Novus Biologicals, CO, 
1:250), and β-actin (Santa Cruz, CA; 1:10,000). Bound antibody was detected by 
InfraRed detectable secondary antibodies (LI-COR, NE; 1:10,000), using LI-COR 
Odyssey infrared scanner for imaging (LI-COR, Lincoln, NE, USA). Blots were 
analyzed using NIH ImageJ software and normalized against the housekeeper 
protein. 
ELISA 
IL-1β was measured from HBMVEC-conditioned media, and TNFα and IL-6 
were measured from BV-2-conditioned media using Enzyme Linked Immunosorbent 
Assay (ELISA) from Biolegend (San Diego, CA, USA; Human IL-1β cat. #437004, 
Mouse TNFα cat. #430904, Mouse IL-6 cat. #431304). The protocol provided by the 






absorbance was detected at 570nm and 450nm using Synergy HTX multi-mode 
reader (Biotek Instruments, Winooski, VT, USA). 
Gelatin Zymography  
Gelatin zymography was performed as previously described (Milner et al., 
2003) to assess the activity of MMP-9 in BV-2 supernatant following treatments. 
Briefly, samples were run on 10% Gelatin Zymogram Plus Protein Gels (Invitrogen, 
Carlsbad, CA, USA). Following electrophoresis, gels were incubated at room 
temperature with zymogram renaturing buffer (Novex, Carlsbad, CA, USA) for 30 min, 
and then incubated with zymogram developing buffer (Novex, Carlsbad, CA, USA) for 
30 min. Gels were further incubated with fresh developing buffer overnight at 37°C. 
Gels were stained with Comassie Blue for 1 hr, and de-stained in diH2O for 1 day. 
Images scanned on Epson Scanner (Epson, Long Beach, CA, USA) and analyzed 
using ImageJ.  
Phagocytosis assay 
Analysis of phagocytic activity of BV-2 was done by measuring uptake of 
fluorescently labeled beads. Protocol for the phagocytosis assay was derived from 
previously published works (Zhang et al., 2017; Cai et al., 2017; Lian et al., 2016; 
Lucin et al., 2013) with modifications. BV-2 cells were plated in 8-well chamber slides 
at a density of 10,000 cells per well in DMEM with 10% FBS and grown for 48 hr. 
Cells were treated as before with HBMVEC-conditioned media for 24 hr.  
Preopsonized latex beads of 1 um diameter (Sigma, cat. #L2778-1ML) were prepared 
in PBS with 50% FBS at 10% (v/v) for 1 hr at 37°C. Beads were then further diluted 
1:100 in DMEM to make a 0.01% (v/v) beads and 0.05% (v/v) FBS solution.  
At the conclusion of 24-hr treatment, BV-2 media was removed and 500 µL of bead 






were rinsed three times with cold PBS. Cells were fixed with 4% paraformaldehyde 
(PFA) in PBS (200 µL per well) for 4 min at room temperature. PFA was removed, 
cells were then blocked and permeabilized with 5% horse serum and 0.3% Triton X-
100 in PBS (200 µL per well) for 30 min at room temperature. Cells were washed 
again with cold PBS three times.  
To image, antifade mounting solution with DAPI (Invitrogen, cat. #S36964) 
was added, slide was covered with a cover slip, and sealed. Imaged beads at 575-
610nm (red) and DAPI at 345-453nm (blue) using the EVOS® FL Auto Cell Imaging 
System (ThermoFisher Scientific, Waltham, MA, USA). ImageJ was used to quantify 
red/blue in all images.  
Statistical Analysis 
Data were analyzed for significance using one-way analysis of variance 
(ANOVA) and multiple comparisons carried out using the post-hoc Bonferroni test on 
GraphPad Prism (version 8.01). Data are represented as Mean +/- SEM. Groups 







Injury of brain endothelial cells by exposure to high-glucose levels and hypoxia  
Human brain microvascular endothelial cells (HBMVECs) were either treated 
with 30 mM glucose (6 hr), exposed to hypoxia (1 hr), or exposed to hypoxia plus 
high glucose (6 hr). LDH release in the supernatant was measured to estimate lethal 
cell injury. Treatment of cells with glucose evoked a small but not significant increase 
in LDH release. In contrast, hypoxia exposure significantly increased LDH release 
compared to untreated controls (p<0.001). The level of LDH detected in cells exposed 
to hypoxia plus high-glucose was higher than levels measured in response to hypoxia 
alone (Fig. 1A). 
To explore indices of non-lethal injury the generation of ROS and release of 
the inflammatory mediator IL-1β were assessed. HBMVECs analyzed using the 
fluorescent probe DCF-DA to measure ROS showed that glucose treatment did not 
alter ROS production compared to control cells, while hypoxia exposure increased 
ROS levels relative to control, but the increase was not significant. HBMVECs 
exposed to both glucose and hypoxia showed significantly increased production of 
ROS compared to control (p<0.001), glucose (p<0.001), or hypoxia (p<0.05) (Fig. 
1B). Measurement of IL-1β levels in supernatant by ELISA indicated that treatment 
with glucose increased IL-1β levels, but the increase was not significant (p=0.11), 
while hypoxia exposure did not affect IL-1β levels. Interestingly, the combination of 
glucose treatment and hypoxia exposure appeared to mitigate the increase evoked 
by glucose alone (Fig. 1C).  







To determine whether injured endothelial cells can affect reactive nitrogen 
species (RNS) generation in microglia, the microglial cell line BV-2 was treated with 
HBMVEC-conditioned media for 24 hr. Conditioned media were collected following 
endothelial cell treatment with either 30 mM glucose (6 hr) (EC-G), exposed to 
hypoxia (1 hr) (EC-H), or exposed to hypoxia plus high glucose (6 hr) (EC-G+H). The 
Griess assay was used to assess nitric oxide (NO) production in the BV-2 
supernatant (Fig. 2A) and iNOS levels in BV-2 lysates were analyzed by western blot 
(Fig. 2B).  
BV-2 cells exposed to conditioned media from glucose-treated endothelial cell 
cultures (EC-G) showed a significant increase in both NO production (p<0.001) (Fig. 
2A) and iNOS expression (p<0.001) (Fig. 2B) compared to BV-2 cells incubated with 
untreated endothelial cell-conditioned media. In contrast, treatment of BV-2 cells with 
conditioned media from hypoxia-exposed endothelial cells (EC-H) did not affect either 
NO production or iNOS levels (Figs 2A, 2B). Treatment of BV-2 cells with conditioned 
media from endothelial cells exposed to both glucose and hypoxia (EC-G+H) 
significantly increased NO production compared to BV-2 cells exposed to conditioned 
media from only glucose-treated endothelial cell cultures (p<0.001). There was no 
significant difference in BV-2 iNOS levels evoked by conditioned media from 
endothelial cells treated with glucose alone and media derived from endothelial cells 
exposed to both glucose and hypoxia (Fig. 2B). 
Glucose-injured microvascular endothelial cells induce changes in inflammatory 
proteins released from BV-2 cells 
The release of cytokines, TNFα and IL-6, by BV-2 cells treated with HBMVEC-
conditioned media for 24 hr was assessed by ELISA. Conditioned media were 






exposed to hypoxia (1 hr) (EC-H), or exposed to hypoxia plus high glucose (6 h) (EC-
G+H). 
BV-2 cells that were treated with media from glucose-injured endothelial cells 
(EC-G) released a significantly (p<0.001) higher level of the pro-inflammatory 
cytokine TNFα compared to microglial cells exposed to control conditioned media 
(Fig. 3A). On its own, conditioned media from hypoxic-injured endothelial cells (EC-H) 
did not alter BV-2 production of TNFα. However, media from endothelial cells that 
were exposed to both glucose and hypoxia (EC-G+H) increased TNFα production in 
BV-2 to higher levels than elicited by media from glucose-only injured endothelial 
cells (p<0.001) (Fig 3A).  
In contrast to the results obtained for TNFα, the data show that conditioned 
media from glucose-injured endothelial cells (EC-G) caused a significant (p<0.001) 
decrease in the release of IL-6, a complex cytokine with both pro- and anti-
inflammatory activities (Fig. 2B). Conditioned media from hypoxic-injured endothelial 
cells (EC-H) did not affect BV-2 IL-6 levels. Also, media from endothelial cells 
exposed to both glucose and hypoxia (EC-G+H) showed a decrease in IL-6 release 
that was comparable to that observed for glucose (EC-G) (Fig. 3B).  
Supernatant from BV-2 cells was collected following treatment with HBMVEC-
conditioned media for 24 hr, as described above, and MMP-9 activity measured by 
gel zymography. Conditioned media from hypoxia-exposed endothelial cells (EC-H) 
did not affect MMP9 activity (Fig. 3B). There was a significant (p<0.001) increase in 
MMP9 activity, relative to controls, elicited media from glucose only (EC-G) and 







BV-2 treated with conditioned media from injured brain endothelial cells show altered 
expression of microglia activation markers 
BV-2 cells were treated with HBMVEC-conditioned media for 24 hr, as 
described above, and western blot was used to determine changes in protein 
expression for several microglia activation- and disease-associated markers (DAMs).  
The expression of Iba1 was significantly (p<0.01) increased in in BV-2 cells treated 
with media from glucose plus hypoxia-injured endothelial cells (EC-G+H) compared to 
controls. Conditioned media from neither glucose alone nor hypoxic injury alone 
affected expression of Iba1 (Fig. 4A). Changes in the expression of BV-2 CD11c and 
CLEC7A in response to endothelial cell conditioned media were similar in pattern, 
differing slightly in magnitude. Conditioned media from glucose-injured endothelial 
cells (EC-G) significantly increased expression of CD11c (p<0.01) (Fig. 4B) and 
CLEC7A (p<0.01) (Fig. 4C) as did conditioned media from glucose plus hypoxia injury 
(EC-G+H) for both CD11c (p<0.01 ) and CLEC7A (p<0.05). Exposure of BV-2 cells to 
HBMVEC-conditioned media collected as described above did not affect expression 
of TREM2 (data not shown).  
Western blot was also used to assess the expression of a homeostatic 
microglia marker, P2Y12. Expression of P2Y12 was significantly decreased when BV-
2 cells were treated with media from glucose injury (EC-G) (p<0.001), hypoxic injury 
(EC-H) (p<0.01), or glucose plus hypoxic injury (EC-G+H) (p<0.001) compared to 
controls (Fig. 4D). Together, these changes indicate a shift towards a DAM 
phenotype in the BV-2 treated with conditioned media from damaged brain 







The phagocytic ability of BV-2 cells is altered in response to conditioned media from 
injured endothelial cells 
BV-2 cells were treated with HBMVEC-conditioned media, as described 
above, and uptake of fluorescently labeled beads measured to assess phagocytic 
ability (Fig. 5A). Bead uptake by BV-2 cells treated with glucose injury media (EC-G) 
was significantly increased (p<0.05) compared to controls. In contrast, conditioned 
media from hypoxic injury (EC-H) did not significantly alter phagocytic ability of BV-2 
cells. However, treatment of BV-2 with conditioned media from glucose plus hypoxia 
injury (EC-G+H) significantly (p<0.001) reduced the phagocytic response compared 









For the first time, we have characterized changes in microglia activation 
following damage to brain endothelial cells in vitro. HBMVECs were treated with high-
glucose with and without hypoxia to assess injury to endothelial cells in diabetes-like 
hyperglycemic conditions. BV-2 microglia were subsequently treated with conditioned 
media from damaged HBMVECs, and analyzed for alterations in inflammatory 
phenotype. We found that endothelial cell damage by glucose and hypoxia produced 
pro-inflammatory alterations to microglia, including increased production of NO and 
TNFα, and increased MMP-9 activity. Additionally, endothelial cell damaged may 
induce a shift towards a disease-associated phenotype in microglia, with BV-2 
showing increased expression of CD11c and CLEC7a following HBMVEC damage, 
and decreased expression of the homeostatic marker P2Y12.  
The alterations found in this study hint at the phenotypic changes found in 
microglia following diabetes-related brain endothelial cell damage. Increases in NO 
and TNFα, like those observed in the EC-G and EC-G+H groups, are indicative of a 
pro-inflammatory microglia phenotype. Similar upregulations have been identified in 
neuroinflammatory disorders, including Alzheimer’s disease [33]. MMP-9 activity has 
likewise been found to be increased in AD [42]. Past research focused on the M1 and 
M2 phenotypes of microglia and often used Iba1 as a marker to identify “activated” 
microglia [43]. Here, the expression of Iba1 was significantly elevated in microglia in 
the EC-G+H group. More recently, microglia research has recognized the complexity 
of microglia activation states, recognizing the previously mentioned DAM as one 
alternative phenotype. DAM exhibit reduction of homeostatic microglia genes and 
increased expression of pro-inflammatory and AD-associated genes [34, 35]. Our 






conversion of microglial towards a DAM-like phenotype, indicated by significantly 
increased expression of CD11c and CLEC7A, as well as significantly decreased 
expression of P2RY12, in the EC-G and EC-G+H groups. However, this conclusion is 
hindered by the additional finding that there is no change in expression of TREM2 
following HBMVEC injury. Past findings indicate that signaling through TREM2 may 
be responsible for the DAM phenotypic switch, suggesting that TREM2 expression 
changes may occur prior to those found in this study.  
These findings also indicate that HBMVEC damage lead to alterations in 
phagocytic function in BV-2 microglia, with EC-G treated BV-2 exhibiting significantly 
increased fluorescent bead uptake, and a significant reduction found for the EC-G+H 
group. Phagocytosis is a key aspect of microglia function in the healthy brain, 
responsible for clearance of debris, apoptotic cells, and synaptic pruning [33]. In AD, 
phagocytic microglia can help to clear aggregated Aβ. However, there is still some 
debate as to whether microglia phagocytosis is beneficial or detrimental in disease 
[44]. Microglia phagocytosis is now thought to play a role in the conversion of 
microglia to DAM, specifically through the ApoE-TREM2 pathway [35]. TREM2 KO 
mice have impaired phagocytosis, related to increased Aβ plaque burden, reduced 
microglia localization to plaques, and increased neuritic dystrophy [33]. Other studies 
indicate that anti-inflammatory microglia highly express phagocytosis-associated 
genes [45]. Therefore, the increased expression of DAM markers along with reduced 
phagocytic ability identified in EC-G+H treated microglia indicates a likely AD-like, 
pro-inflammatory phenotype.  
As indicated previously, endothelial cells may function as a key driver of the 
brain’s inflammatory response, including in AD. Previous research has found that 






been related to neuroinflammation and the activation of pro-inflammatory microglia, 
including thrombin, MMPs, and a number of cytokines [22, 46-49]. Our findings 
indicate a role for vascular-derived IL-1β and ROS in propagating the inflammatory 
cycle in the brain. Here, brain endothelial cells injured by glucose and glucose plus 
hypoxia exhibit an upregulation in IL-1β and ROS, respectively, and these increases 
were correlated with the up-regulation of pro-inflammatory markers in microglia. IL-1β 
acts as an amplifier of immune reactions, and can stimulate a number of downstream 
neuroinflammatory processes. In the periphery, IL-1β stimulated the differentiation of 
monocytes to M1-like macrophages [50]. In vitro, IL-1β enhanced microglia release of 
NO following LPS stimulation [51]. High levels of oxidative stress have been identified 
in the AD brain, and ROS function as mediators of injury and inflammation [52]. ROS-
mediated signaling pathways are relevant for the induction of inflammatory signaling, 
including the stimulation of pro-inflammatory cytokines and NO [53]. TNFα, NO, and 
MMP9 are all produced in response to both oxidative stress and cytokine signaling 
[42, 52-54], highlighting the potential for these endothelial-derived mediators to 
activate a pro-inflammatory response like that found in our co-culture system. Of 
particular interest, both IL-1 and ROS activate NF-κβ-mediated pro-inflammatory 
signaling that stimulates the production on cytokines [52, 53, 55], providing one 
possible mechanism by which endothelial produced mediators may signal through. In 
some cases, including expression of iNOS and induction of phagocytosis, EC-G+H 
microglia showed reduced up-regulation in inflammatory mediators compared to EC-
G. This finding suggests that there may also be mechanisms through which microglia 
are differentially activated in response to alternative inflammatory mediators, for 






It is interesting that hypoxic damage to endothelial cells alone did not show 
significant effects on microglia. Others have found exposure to high-glucose induced 
increased expression of pro-inflammatory cytokines in BV-2 and primary microglia, 
including TNFα and IL-6 [56-58]. Additionally, Zhang et al., 2015 found that exposure 
to high-glucose enhanced microglia response to LPS [59]. It is therefore plausible that 
the presence of high glucose levels exacerbates the response of microglia to 
endothelial cell damage, as indicated by the strong increases in pro-inflammatory 
mediators found in both glucose-associated groups in this study  
This novel study is the first to look to characterize the effects of 
hyperglycemia-related brain endothelial cell injury on microglia activation and 
function. Though this simplified in vitro system contains some limitations, it does 
highlight an important connection between the cerebrovascular system and microglia 
in dictating the neuroinflammatory response. A strengthened understanding of how 
endothelial cell damage can alter microglia function and lead to an inflammatory 
response may help us to better characterize the neuroinflammation found in 
Alzheimer’s and other neurodegenerative disorders. Additionally, greater knowledge 
of the mediators responsible for this endothelial cell-microglia crosstalk may help 
inform novel therapeutic targets and techniques for mitigating disease-related 










Figure 1 | HBMVEC injury following treatment with high glucose with and 
without hypoxia. Human brain microvascular endothelial cells (HBMVECs) were 
exposed to high-glucose, one-hour hypoxia, or a combination of both. Cells and 
supernatant were collected to assess measures of cellular injury: (A) lactate 
dehydrogenase (LDH) release as a measure of cell toxicity, (B) reactive oxygen 
species (ROS) production measured with DCF-DA, represented as relative 
fluorescence units (RFU), and (C) IL-1β secretion in the supernatant measured by 










Figure 2 | HBMVEC injury induces increased nitric oxide production by BV-2 
microglia. Conditioned media from injured human brain microvascular endothelial 
cells (HBMVECs) was used to treat BV-2 microglia for 24 hours. Supernatant and cell 
lysate were collected following treatments and used to measure (A) Nitric Oxide (NO) 
in the supernatant using Griess reagent and (B) expression of iNOS in the lysate by 
western blot. **p<0.01 vs. Control, ***p<0.001 vs. Control, ###p<0.001 vs. Glucose, 













Figure 3 | HBMVEC injury induces increased production of inflammatory 
mediators by BV-2 microglia. Conditioned media from injured human brain 
microvascular endothelial cells (HBMVECs) was used to treat BV-2 microglia for 24 
hours. Supernatant from BV-2 was collected following treatments. ELISA was used to 
measure secretion of (A) TNFα and (B) IL-6. (C) The enzymatic activity of MMP-9 
was measured by gel zymography. ***p<0.001 vs. Control, ###p<0.001 vs. Glucose, 








Figure 4 | BV-2 treated with conditioned media from injured HBMVEC show 
altered expression of microglia activation markers. Conditioned media from 
injured human brain microvascular endothelial cells (HBMVECs) was used to treat 
BV-2 microglia for 24 hours. Western blot was used to assess the expression of 
microglia markers, (A) Iba1, (B) CD11c, (C) CLEC7A, and (D) P2Y12. *p<0.05 vs. 
Control, **p<0.01 vs. Control, ***p<0.001 vs. Control, #p<0.05 vs. Glucose, ^p<0.05 








Figure 5 | BV-2 treated with conditioned media from injured HBMVEC show 
altered phagocytic ability. Conditioned media from injured human brain 
microvascular endothelial cells (HBMVECs) was used to treat BV-2 microglia for 24 
hours. BV-2 were then incubated with fluorescently labeled beads for 1 hour. Cells 
were then imaged (EC-C, EC-G, EC-H, EC-G+H left to right) (A), and bead uptake 
per cell was quantified (B) as a measure of phagocytic activity. *p<0.05 vs. Control, 
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Effects of Apolipoprotein E isoforms on glial and neuronal cells in vitro 








Mutations to the cholesterol transport protein apolipoprotein E (ApoE) have been 
identified as a major risk factor for the development of sporadic or late-onset 
Alzheimer’s disease (AD), with the E4 allele representing an increased risk and the 
rare E2 allele having a reduced risk compared to the primary E3 form. The reasons 
behind the change in risk are not entirely understood, though ApoE4 has been 
connected to inflammation-related changes in both the brain and the periphery. It is 
our hypothesis that ApoE4 acts on astrocytes, microglia, and neurons to promote 
inflammation and neuronal injury. To test this hypothesis we compared the effects of 
ApoE isoforms in vitro on human astrocytes, a human immortalized microglia cell line 
(HMC3), and the human neuronal cell line SH-SY5Y. Cells were treated for 24 hours 
with or without recombinant ApoE2, ApoE3, or ApoE4 (20 nM) and inflammation, 
activation, and toxicity markers assessed. Our results indicated the expression of 
inflammatory cytokines IL-1β, TNFα, and IL-6 in human astrocytes was increased in 
response to all ApoE isoforms, with ApoE4 evoking the highest level of cytokine 
expression. ApoE4 increased inflammatory cytokines but not oxidative stress proteins 
in human astrocytes, as there was no measurable change in expression of either 
NOX4 or iNOS in astrocytes exposed to ApoE isoforms. In response to ApoE2 or 
ApoE3, microglial cells showed reduced levels of microglial activation markers 
TREM2 and Clec7a, while ApoE4 induced increased levels of both markers. We 
examined the effects of ApoE isoforms on neuronal viability and showed that ApoE2 
promoted neuron survival through increased BDNF release from astrocytes, while 
ApoE4 inhibited BDNF release. In addition, ApoE4, acting directly on neurons, 
caused neuronal toxicity and reduced cell viability. Overall, these results suggest that 






the deleterious effects of ApoE4 on these cells may, in part, contribute to its role as a 







The most significant known genetic risk factor for late-onset Alzheimer’s 
disease (AD) is an allele variant of apolipoprotein E (ApoE), a protein involved in lipid 
metabolism and cholesterol homeostasis [1]. The ApoE gene has three polymorphic 
alleles that occur in humans, E2, E3, and E4. These alleles occur at different 
frequencies, with E3 occurring most frequently at 65-70%, followed by E4 and E2 [1]. 
However, the frequency of the E4 allele is substantially increased from 13% to 
approximately 40% in AD patients compared to healthy counterparts [2]. Population 
studies have shown that the E4 allele is associated with a significantly elevated 
likelihood for developing Alzheimer’s, with just one copy conferring a 4-fold increased 
risk for developing AD and an 8 year earlier average age of onset compared to 
individuals homozygous for E3. On the other hand, the E2 variant seems to have 
protective effects, with the risk for developing AD significantly lower in individuals 
carrying one E2 allele [1, 2]. Although the relationship between ApoE allele and AD 
has been well established, the mechanisms behind these risk differences have not 
been well characterized.  
ApoE is primarily synthesized in the liver, but the brain synthesizes its own 
ApoE as well. In the brain, ApoE mRNA has been found in the cerebral cortex, 
hippocampus, cerebellum, and medulla [3]. ApoE is synthesized primarily by 
astrocytes, but it has also been found to be produced by oligodendrocytes, microglia, 
and neurons under stress conditions [1]. Due to its primary function as a lipid 
transport molecule, ApoE has largely been studied for its role in Aβ clearance in AD. 
ApoE4 impairs Aβ clearance compared to ApoE3, and increases amyloid formation in 
the brain [4]. Brain plaque load is the lowest in ApoE2 and the highest in ApoE4 






ApoE in the brain as a mediator of cerebrovascular function, neuroinflammation, 
synapse formation, and neurotoxicity [2]. 
A clear role for ApoE in the modulation of the innate immune system has been 
identified. Neuroinflammation is known to play a key role in the pathological 
progression of AD [5-7], and ApoE4 is associated with pro-inflammatory changes in 
both the central nervous system (CNS) and periphery [8]. Post-mortem ApoE4-
expressing brain samples exhibit upregulation in proteins related to the regulation of 
inflammatory response compared to both ApoE3 and ApoE2-expressing tissue [9]. 
Specifically, a clear role for mediating microglia phenotype and function has been 
identified for ApoE. Microglia expressing human ApoE4 exhibit significantly increased 
production of pro-inflammatory mediators, including tumor necrosis factor-α (TNFα), 
interleukin (IL)-6, and nitric oxide (NO) [10-13]. More recent research using induced 
pluripotent stem cell (iPSC)-derived microglia expressing human ApoE found that 
ApoE4 microglia have impaired migration and reduced phagocytic function. These 
microglia also display enhanced cytokine production in response to LPS compared to 
ApoE3 expressing microglia [14]. Further support for the ability of ApoE to regulate 
neuroinflammatory processes comes from the finding that ApoE signaling via 
triggering receptor expressed on myeloid cells 2 (TREM2) regulates a switch in 
microglia towards a neurodegenerative phenotype. Targeting ApoE signaling has the 
ability to restore homeostatic function in microglia [15]. Therefore, ApoE modulation 
of the innate immune system, particularly through alterations in microglia phenotype, 
may play a key role in ApoE-related AD pathology.  
Along with neuroinflammatory effects on glial cells in the brain, ApoE isoforms 
have also been shown to differentially modulate cerebrovascular function and blood-






neuroinflammation and damage [2]. In humans, there is a relationship between 
ApoE4-mediated BBB breakdown and cognitive decline [16]. ApoE4 produces BBB 
breakdown in vitro via activation of cyclophilin A (CypA)-NF-κβ-matrix 
metalloproteinase-9 (MMP-9) signaling, but this same activation does not occur in 
ApoE2 or ApoE3. In vivo, astrocyte secreted ApoE3, but not ApoE4, suppressed the 
activation of CypA-NF-κβ-MMP9 signaling [17]. In vitro, endothelial cells that express 
ApoE4 have significantly increased production of inflammatory cytokines and 
enhanced thrombosis compared to cells expressing ApoE3 [18]. Together, these 
findings indicate that ApoE4 promotes vascular activation and vascular-based 
inflammation that likely contributes to the pro-inflammatory effects of ApoE4 in AD-
related pathology.   
ApoE isoforms may also regulate neuronal survival or toxicity, a key aspect of 
neurodegenerative pathological processes in AD. Directly, treatment of iPSC-derived 
neurons with recombinant ApoE2/3/4 stimulates various signal transduction cascades 
with different levels of potency. One such cascade is amyloid precursor protein (APP) 
synthesis and synapse formation, which is enhanced in ApoE4 treated neurons and 
reduced in ApoE2 treated compared to ApoE3 [19]. ApoE4 has been shown to 
promote tau phosphorylation and neurotoxicity [2], as well as impair synaptogenesis 
[3]. ApoE4 is more susceptible than other isoforms to proteolytic cleavage, and this 
cleavage fragment is neurotoxic [20]. Indirectly, ApoE may also influence synapse 
formation and neuron survival through astrocyte activity. ApoE3 enhances astrocyte 
phagocytosis of synapses, while ApoE4 decreases the same activity [21]. Astrocytes 
are also a primary producer of neurotrophic support, including brain derived 
neurotrophic factor (BDNF). BDNF is decreased in the serum and brain of AD 






to modulate astrocyte production and secretion of BDNF [24]. Overall, these findings 
further suggest that ApoE isoform-specific effects on cells in the brain, including 
neurons and astrocytes, is responsible for the substantially increased ApoE4-related 
AD risk.  
The goal of this study was to better understand how the ApoE isoforms 
(ApoE2/3/4) confer differential AD-related risk by assessing cell-specific ApoE-related 
neuroinflammatory and neurotoxic effects. It is our hypothesis that markers of 
inflammation and neurotoxicity are increased in response to ApoE4 compared to E2 
and E3. Furthermore, we hypothesize that ApoE2 will reduce these same markers, 
highlighting its neuroprotective role. Human microglia, astrocytes, and neurons were 
treated with ApoE2/3/4 in vitro, and the effects of the ApoE isoforms on markers 
related to neuroinflammation and neurotoxicity were then assessed. The findings 
here help to better characterize the isoform and cell-specific effects of ApoE that may 







Cell culture and Other Reagents 
Human immortalized microglia cell line (HMC3; CRL-3304) and Eagle’s 
Minimum Essential Medium (EMEM; 30-2003) were purchased from ATCC 
(Manassas, VA, USA). Human primary astrocytes (#1800) and astrocyte medium 
(#1801) along with astrocyte growth supplements were purchased from ScienCell 
Research Laboratories (Carlsbad, CA, USA). Human neuroblastoma cells (SH-SY5Y) 
were kindly provided by Dr. Navindra Seeram (University of Rhode Island, Kingston, 
RI, USA). Dulbecco’s Modified Eagle Medium (DMEM), DMEM/F12, Fetal Bovine 
Serum (FBS), Bovine Serum Albumin (BSA), poly-L-lysine, and recombinant human 
ApoE2 (rh-ApoE2), ApoE3 (rh-ApoE3), and ApoE4 (rh-ApoE4) were purchased from 
Sigma Aldrich (St. Louis, MO, USA).  
Cell Culture and Treatments 
HMC3 were grown and maintained in EMEM with 10% FBS. Treatment media 
was serum free EMEM. Human primary astrocytes were plated on poly-L-lysine 
coated plates and maintained in astrocyte medium with growth supplements and 2% 
FBS, according to protocols provided by ScienCell. For treatments, media was 
replaced with serum-free DMEM. SH-SY5Y were grown and maintained in 
DMEM/F12 with 10% FBS, and treatments were done in serum-free DMEM/F12.   
Rh-ApoE2/3/4 were dissolved in PBS pH 7.4 to make a stock at 6 μM. All cells 
were treated with cholesterol (100 µM) (control) with or without 20 nM rh-
ApoE2/ApoE3/ApoE4 for 24 hr. ApoE and cholesterol were added separately to 
cultures. 






The viability of SH-SY5Y was assessed following treatments with rh-
ApoE2/3/4. Cells were seeded in 96-well plates at 100,000 cells/mL, and were 
allowed to adhere for 48 hr. They were then treated with cholesterol with or without 
rh-ApoE2/3/4 for 24 hr. Cellular viability was determined as a percentage of control 
(cholesterol) by CellTiter 96 ® Aqueous One Solution Cell Proliferation Assay (MTS; 
Promega, Madison, WI, USA), and read for absorbance at 490nm on the Synergy 
HTX multi-mode reader (Biotex Instruments, Winooski, VT, USA).  
Cytotoxicity Assay 
Cellular toxicity of SH-SY5Y following treatments was assessed by measuring 
lactate dehydrogenase (LDH) release in the conditioned media. Supernatant from 
cells was collected and transferred to a 96-well plate. Total LDH was assessed using 
a cytotoxicity detection kit (Millipore Sigma, Burlington, MA, USA). Samples were 
incubated with chromogenic dye and catalyst, then absorbance was read at 490nm 
using a Synergy HTX multi-mode reader (Biotek Instruments, Winooski, VT, USA).  
Western Blot 
Western blot was used to measure protein expression in all cell types 
following 24 hr treatment with rh-ApoE2/3/4. Cells were lysed in Tris-HCl buffer with 
protease inhibitors. Lysates were mixed with 40% 4x Laemmli Sample Buffer 
(BioRad, Hercules, CA, USA) with 10% 2-mercaptoethanol. Samples were run by 
SDS-PAGE on gradient gels (Invitrogen, Carlsbad, CA, USA) and transfer was done 
by dry blotting to Nitrocellulose Membranes (iBlot, Invitrogen, Carlsbad, CA, USA). All 
membranes were blocked in 5% BSA in Tris buffered saline (TBS) containing 0.05% 
Tween-20. Membranes were incubated with primary antibody overnight at 4°. Primary 
antibodies include IL-6 (Bioss, MA; 1:500), TNFα (Novus Biologicals, CO; 1:500), IL-






TREM2 (Novus Biologicals, CO; 1:500), Clec7a (Novus Biologicals, CO; 1:500), 
BDNF (Abcam, MA; 1:1,000), and β-Actin (Santa Cruz, CA; 1:10,000). Bound 
antibody was detected by infrared secondary antibodies (Li-COR, NE; 1:10,000), and 
imaged on LiCor Odyssey (Li-COR Biosciences, Lincoln, NE, USA). Quantification of 
western blots was done in ImageJ, and values for each protein were normalized to β-
Actin. 
Statistical Analysis 
All data were analyzed for significance using one-way analysis of variance 
(ANOVA) and multiple comparisons post-hoc were completed using Bonferroni test 
on GraphPad Prism (version 8.04; GraphPad, CA, USA). Data represented as 








ApoE4 increases inflammatory cytokines but not oxidative stress proteins in human 
astrocytes 
ApoE4 is associated with increased inflammation in various model systems 
and disease states [8, 25, 26]. Recently, the regulation of cholesterol by ApoE4 in the 
brain has been shown to be cell-type specific [27]. While astrocytes have been widely 
studied for their role in ApoE4-related lipid homeostasis and glucose metabolism [28], 
less is known about their function in ApoE4-associated neuroinflammation. Here we 
explored the ability of ApoE isoforms to affect expression of pro-inflammatory 
cytokines in human astrocytes. Human astrocytes were treated with recombinant 
ApoE isoforms, ApoE2, ApoE3, or ApoE4 for 24 hr and cell lysate analyzed (Fig. 1). 
Expression of inflammatory cytokines IL-1β (Fig. 1A), TNFα (Fig.1 B), and IL-6 
(Fig. 1C) in human astrocytes was evaluated by western blot. Treatment of astrocytes 
with all three ApoE isoforms significantly (p<0.001) increased IL-1β expression 
compared to untreated control cells (Fig. 1A). However, ApoE4 evoked the highest 
level of IL-1β, which was significantly higher than that observed with either ApoE 2 
(p<0.01) or ApoE 3 (p<0.05). ApoE2 and ApoE3 both appeared to elicit a small but 
not significant increase in TNFα. In contrast, ApoE4 significantly (p<0.05) increased 
TNFα compared to control as well as to both ApoE2 and ApoE3 (Fig. 1B). The ability 
of ApoE isoforms to affect IL-6 expression followed a pattern similar to that observed 
for IL-1β. Treatment of astrocytes with all three ApoE isoforms significantly (p<0.001) 
increased IL-6 expression compared to untreated control cells (Fig. 1C). However, 
ApoE4 evoked the highest level of IL-6, which was significantly (p<0.05) higher than 






Inflammation and oxidative stress are related processes and often respond 
similarly to external stimuli. To determine whether oxidative stress is affected by 
ApoE isoforms, human astrocytes were treated as described above and analyzed for 
the expression of the oxidative stress proteins NADPH oxidase 4 (NOX4) and 
inducible nitric oxide synthase (iNOS). The data showed that there was no 
measurable change in expression of either NOX4 or iNOS in response to ApoE2, 
ApoE3, or ApoE4 (Table 1).  
ApoE4 enhances the inflammatory activation of microglia 
Microglia exhibit a range of phenotypes and activation states in response to 
extracellular signals. We examined the effect of ApoE isoforms on the human 
microglial cell line HMC3. Cells were treated with recombinant ApoE isoforms, 
ApoE2, ApoE3, or ApoE4 for 24 hr and cell lysate analyzed. Western blot was used 
to measure the expression of cytokines and markers related to microglial activation 
(Fig. 2). 
We examined the effect of ApoE isoforms on both the pro-inflammatory 
cytokine TNFα as well as on IL-6, a complex cytokine with both pro- and anti-
inflammatory properties. It should be noted that the response/activity of HMC3 under 
control conditions (untreated) appears elevated. Although statistically significantly 
conclusions are difficult to draw, clear trends are evident. Exposure to ApoE2 or 
ApoE 3 lowers expression of TNFα while treatment with ApoE4 increases TNFα level 
(Fig. 2A). In contrast, neither ApoE2 nor ApoE3 affected IL-6 expression while ApoE4 
significantly (p<0.05) decreased IL-6 expression compared to control (Fig. 2B). 
Microglia have been shown to take on an alternate activation state in AD, termed 
disease-associated microglia (DAM) [15]. DAMs are characterized by decreased 






inflammatory indicators. HMC3 were treated as described above and western blot 
was used to assess the expression of markers related to microglia activation, TREM2 
and CLEC7a (Figs. 2C, 2D). Similar to the pattern noted above, a high level of 
activation was observed in untreated (control) HMC3. Despite the elevated basal 
response of HMC3, the data showed that treatment with either ApoE2 or ApoE3 
diminished expression of TREM2 and CLEC7a while ApoE4 exposure increased 
levels of both TREM2 (Fig. 2C) and CLEC7a (Fig. 2D). Expression of both TREM2 
and CLEC7a was significantly (p<0.05) elevated in the ApoE4 treated group 
compared to ApoE3 (Fig. 2C-D).  
ApoE2 promotes neuron survival while ApoE4 reduces neuronal viability 
Studies have indicated reduced levels of the neurotrophic factor BDNF in AD 
patients compared to healthy controls [22, 23]. Astrocytes are a primary source of 
BDNF in the brain. We therefore sought to investigate the connection between ApoE 
isoform and BDNF expression levels. Human astrocytes were treated with 
recombinant ApoE isoforms, ApoE2, ApoE3, or ApoE4 for 24 hr, conditioned-media 
collected, and BDNF expression level evaluated by western blot (Fig. 3A). 
Treatment of astrocytes with ApoE2 significantly (p<0.001) increased the level of 
BDNF detected in the media (Fig. 3A). ApoE3 appeared to slightly increase BDNF, 
although to a significantly (p <0.05) lower extent than ApoE2. Exposure of astrocytes 
to ApoE4 had no effect on release of BDNF (Fig. 3A). 
To further investigate the potential neuroprotective and neurotoxic effects of 
ApoE isoforms, we directly exposed the neuronal cell line SH-SY5Y to recombinant 
ApoE2, ApoE3, or ApoE4 for 24 hr and assessed cellular viability and toxicity. 
Cellular viability was significantly (p<0.01) increased in ApoE2 treated SH-SY5Y 






compared to both ApoE2 and ApoE3 (Fig. 3B). SH-SY5Y cells exposed to ApoE 
isoforms were also analyzed for cellular toxicity. Neither ApoE2 nor ApoE3 had any 
effect on release of LDH. In contrast, ApoE4 treated cells display significantly 
(p<0.05) increased cytotoxicity compared to untreated controls, with an increase in 
LDH release of 14% ± 4.164 (Table 2). Together, these findings indicate that ApoE2 
is neuroprotective through both increased BDNF and direct action on neurons. 







ApoE4 is the strongest known genetic risk factor for AD, while ApoE2 appears 
to be protective against AD. While the different levels of risk related to each isoform 
have been well established, the mechanism responsible for this relationship is still not 
entirely understood. Here, we investigated the cell type-specific effects of ApoE2/3/4 
in the brain on markers related to key aspects of AD pathology neuroinflammation 
and neurotoxicity. Our results showed that ApoE acts in an isoform-specific manner to 
modulate pro-inflammatory activity of microglia and astrocytes, and affects neuron 
survival through both direct and indirect mechanisms.    
We investigated the expression of pro-inflammatory cytokines in both 
microglia and astrocytes following treatment with ApoE isoforms. ApoE4 treatment 
increased the production of TNFα in relation to both ApoE2 and ApoE3, but 
significantly reduced the expression of IL-6 in microglia. While the pro-inflammatory 
activation of microglia by ApoE4 had been well-established, less is known about the 
ApoE-related inflammatory effects in astrocytes. Astrocytes, like microglia, are key 
regulators of the brain’s inflammatory response, and have been implicated in AD-
related inflammatory and pathological processes [29]. Astrocytes have been found to 
produce inflammatory cytokines, including IL-6 and TNFα, following traumatic injury 
and ischemia [30]. Here, we show that ApoE treatment significantly increases the 
production of pro-inflammatory cytokines IL-1β, IL-6, and TNFα in a dose-dependent 
manner, with ApoE2 representing the lowest cytokine expression and ApoE4 
representing the highest. TNFα is a key mediator in neuropathology and has been 
found to promote excitotoxicity, synaptic loss, and exacerbated amyloidogenesis in 
AD. Additionally, there is evidence to suggest elevated serum levels of TNFα in AD 






astrocytes in response to injury [31], and here TNFα expression is increased by 
ApoE4 in both cell types. Similar to TNFα, IL-1β is a pleiotropic cytokine that amplifies 
immune reactions [33] and is elevated in the CSF of AD patients [34]. Both TNFα and 
IL-1 can induce increased production of IL-6 and other inflammatory mediators via 
NF-κβ activation [32]. Mice with astrocyte-targeted enhanced IL-6 production exhibit 
neurodegeneration and demyelination, along with decreased hippocampal long-term 
potentiation (LTP) and learning impairments. Microglia in these mice also have 
enhanced pro-inflammatory activation [35]. However, IL-6 signaling is largely context 
dependent, and has been shown to mediate both pro- and anti-inflammatory, 
protective processes [36], which may in part help to explain the reduction in IL-6 
production by ApoE4-treated microglia. These findings highlight a previously 
underexplored role for ApoE in modulating the inflammatory state of astrocytes, and 
suggest that ApoE4 may influence AD pathology via increased production of 
inflammatory cytokines by both astrocytes and microglia.  
The results of this study also reveal the ApoE-related differential activation of 
microglia. HMC3 microglia were treated with ApoE2/3/4 and markers related 
microglial activation state were assessed. DAM refers to a subset of microglia 
identified in the AD brain that have dysregulated expression of sensing, house-
keeping, and host-defense genes [15, 37, 38]. DAM are largely localized around Aβ 
plaques and display elevation of lipid metabolism and phagocytic activity-related 
genes, as well as genes related to increased AD risk [15]. ApoE is known to play a 
key role in the phenotypic of switch of microglia through signaling at TREM2 [15]. 
Here, we further the idea that ApoE4 enhances activation of the DAM phenotype by 
showing that ApoE4 treatment increased the expression of both the receptor TREM2 






ApoE4 may confer increased risk for AD through enhanced activation of DAM, and 
related, down-stream pro-inflammatory and disease progressing effects. An 
alternative explanation of these findings is that ApoE2 and ApoE3 act in a protective 
manner compared to the cholesterol control, suppressing expression of DAM-related 
markers, while ApoE4 represents a potential loss-of-function.   
Finally, our findings highlight the idea that ApoE2 is neuroprotective while 
ApoE4 is neurotoxic through both direct and indirect mechanisms. Human 
neuroblastoma cells (SH-SY5Y) were treated with recombinant ApoE2/3/4 and 
cellular viability and toxicity were assessed. ApoE2 significantly increased cellular 
viability, while ApoE4 significantly decreased viability and increased toxicity. Synapse 
loss and progressive neuron death are core pathological hallmarks of AD, and these 
losses correlate with cognitive impairment [39]. Therefore, ApoE4 may help to 
promote AD pathological progression by enhancing neuron death, while ApoE2 
protects against these same processes. As before, this may be a case of ApoE2 
working in a protective manner against the cholesterol control, while ApoE4 
represents a loss of this protective function. Additionally, human astrocytes were 
treated with recombinant ApoE2/3/4 and the secretion of the neurotrophic factor 
BDNF was assessed. Secretion of growth factors, including BDNF, is a major function 
of astrocytes [29]. BDNF has been found to be reduced in human AD, and a previous 
study found that ApoE isoforms modulated astrocyte production of specific BDNF 
isoforms [22-24]. Here, we show that ApoE2 significantly increased astrocyte 
secretion of mature BDNF. Peripheral BDNF has been found to protect against AD, 
with one standard deviation higher serum BDNF conferring a 33% decreased risk for 
AD [40]. BDNF enhances neurogenesis and neurotransmission, promotes synaptic 






[22]. Additionally, BDNF has been found to have anti-apoptotic and anti-oxidant 
functions in experimental models of neurodegenerative disease [41]. Taken together, 
these findings suggest that ApoE2 reduces risk for AD by acting in a neuroprotective 
manner, through both direct and indirect action at neurons. On the other hand, ApoE4 
may further promote AD-related risk through its neurotoxic effects in the brain.   
Overall, our findings highlight that ApoE acts as a multi-functional mediator in 
AD-related pathological processes. In an isoform-specific manner, ApoE regulates 
neuroinflammation and neurotoxicity through direct actions on microglia, astrocytes, 
and neurons. In general, ApoE4 promotes pro-inflammatory and neurotoxic 
processes, while ApoE2 acts in a neuroprotective manner, highlighting the differential 
risk associated with these ApoE isoforms in the development of AD. Additionally, 
these findings suggest that targeting ApoE-related signaling may be a potential 
therapeutic strategy for mitigating multiple AD-related pathological processes in 









Figure 1 | In vitro expression of inflammatory cytokines by astrocytes treated 
with ApoE isoforms. Human primary astrocytes were grown in vitro and treated for 
24 hr with 100  µM cholesterol (control) with or without recombinant ApoE2/3/4 (20 
nM). Following treatment, cell lysate was collected and western blot was used to 
assess the expression of inflammation-related proteins: A) IL-1β, B) TNFα, and C) IL-
6. N=3, *p<0.05 vs. Control, **p<0.01 vs. Control, ***p<0.001 vs. Control, #p<0.05 vs. 











Control ApoE2 ApoE3 ApoE4 
ANOVA 
result 
NOX4 100 ± 6.32 90.17 ± 6.01 86.22 ± 3.67 99.45 ± 5.01 p=0.2554 
iNOS 100 ± 10.03 101.95 ± 9.57 99.95 ± 6.26 89.91 ± 11.99 p=0.8139 
 
Table 1 | Expression of oxidative stress markers by astrocytes treated with 
ApoE2/3/4 in vitro. Human primary astrocytes were grown in vitro and treated for 24 
hr with 100 μM cholesterol (control) with or without recombinant ApoE2/3/4 (20 nM). 
Following treatment, cell lysate was collected and western blot was used to assess 
the expression of oxidative stress-related enzymes NOX4 and iNOS. Data are 
represented as percent of control Mean ± SEM, N=3. One-way ANOVA was used to 









Figure 2 | In vitro expression of inflammatory cytokines and activation markers 
by microglia treated with ApoE isoforms. Human immortalized microglia cell line 
(HMC3) were grown in vitro and treated for 24 hr with 100 µM cholesterol (control) 
with or without recombinant ApoE2/3/4 (20 nM). Following treatment, cell lysate was 
collected and western blot was used to assess the expression of pro-inflammatory 
cytokines: A) TNFα and B) IL-6. Expression of markers related to disease-associated 
microglia were also evaluated: C) TREM2 and D) CLEC7a. N=3, *p<0.05 vs. Control, 








Figure 3 | Evaluation of neurotrophic factors and neuron survival following 
treatment with ApoE isoforms in vitro. Human primary astrocytes and human 
neuroblastoma cell line (SH-SY5Y) were grown in vitro and treated for 24 hr with 100 
µM cholesterol (control) with or without recombinant ApoE2/3/4 (20 nM). A) Following 
treatment, astrocyte supernatant was collected and western blot was used to assess 
the expression of secreted BDNF. B) SH-SY5Y viability was measured by MTS. N=3-
5, **p<0.01 vs. Control, ***p<0.001 vs. Control, ###p<0.001 vs. ApoE3, ^p<0.05 vs. 










ApoE2 ApoE3 ApoE4 
Percent change 
vs. Control 
+ 2.6 ± 3.05 + 2.7 ± 4.16 + 14 ± 4.16* 
 
Table 2 | SH-SY5Y toxicity following treatment with ApoE2/3/4 in vitro. Human 
neuroblastoma cell line (SH-SY5Y) was grown in vitro and treated for 24 hr with 100 
μM cholesterol (control) with or without recombinant ApoE2/3/4 (20 nM). Following 
treatment, cellular release of lactate dehydrogenase (LDH) was assessed as a 
measure of cellular toxicity. Data are represented as percent change versus control 
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Sex-specific effects of Apolipoprotein E4 on markers of vascular function and 
inflammation in the brain in vivo 








Inheritance of the apolipoprotein E4 (ApoE4) is considered a major genetic risk factor 
for the development of sporadic or late-onset Alzheimer’s disease (AD). The reasons 
behind the increase in AD risk are not entirely understood, though ApoE4 has been 
connected to inflammation and oxidative stress in both the brain and the periphery. 
Also, the prevalence of AD is significantly increased in females compared to males. 
Interestingly, the ApoE4-associated risk for AD is substantially higher for females than 
males, conferring an approximately 2-fold higher risk in females. It is our hypothesis 
that markers of vascular dysfunction, inflammation, and oxidative stress are increased 
in response to apolipoprotein E4, and that these changes occur to a greater extent in 
females. Male and female mice expressing human ApoE4 were analyzed for whole-
brain protein expression by western blot at 10 months of age and compared to age-
matched wild-type controls. Our data indicate that expression of the blood-brain 
barrier related junctional proteins claudin-5 and occludin are decreased in response 
to ApoE in a sex-specific manner, with claudin-5 decreased in females and occludin 
diminished in male ApoE4 mice. Mice expressing the E4 allele exhibited changes in 
expression of inflammation-related proteins (TNF-α, IL-6, IL-1β), and oxidative stress 
related proteins (iNOS, eNOS, and NOX4). The results indicated sex-related 
differences in the modulation of inflammatory/oxidant proteins. ApoE4 females 
displayed decreased eNOS expression, along with increases in iNOS, IL-1β, and 
TNF-α. Interestingly IL-6, a cytokine with pro- and anti-inflammatory properties, was 
increased in male ApoE4 but decreased in female ApoE4 mice. The effect of ApoE4 
on expression of glial activation markers GFAP and Iba1 appears sex-specific, with 
female ApoE4 mice exhibiting higher GFAP and male ApoE4 mice demonstrating 






wild-type mice compared to male wild-type. Overall, results indicate that the ApoE4 
isoform promotes an inflammatory-oxidative state in female mice to a greater extent 
than in males. Further studies are needed to better understand the mechanism by 







Cardiovascular risk factors (CVRFs) such as diabetes, hypoxia, and 
inheritance of the apolipoprotein E4 (ApoE4) allele are linked to the pathogenesis of 
Alzheimer’s disease (AD), although the mechanisms whereby these risk factors lead 
to neurodegenerative injury and dementia have not been well defined [1-7]. In 
particular, ApoE4 is the most significant genetic risk factor for late-onset AD [8]. There 
are three polymorphic variants of ApoE, E2, E3, and E4. The E3 allele is the most 
common, while the worldwide frequency of E4 is only 13.7%. However, the frequency 
of E4 increases to approximately 40% in AD patients [9]. Additionally, the presence of 
the E4 allele leads to increased prevalence and lower age of onset of AD [10]. 
Further evidence for ApoE4’s association with AD comes in the findings that ApoE4 is 
related to impaired cognition in midlife as well as an increased conversion of mild 
cognitive impairment (MCI) to AD [11-13]. In particular, ApoE4 acts synergistically 
with CVRFs to exacerbate cognitive decline in cardiovascular disease and AD [14]. 
For example, the Honolulu-Asia Aging Study found that the association between type 
II diabetes mellitus (T2D) and AD was stronger in the presence of ApoE4, particularly 
producing a higher number of neuritic plaques and neurofibrillary tangles [15].  
The prevalence of AD is significantly increased in females compared to males 
[16]. The ApoE4-associated risk for AD is also substantially higher for females than 
males, conferring an approximately 2-fold higher risk in females [17, 18]. The 
mechanisms behind this gender-related effect have not been well studied. ApoE4 is 
associated with worsened cognitive decline in women, as well as a higher likelihood 
of conversion from MCI to AD [18]. This observation is further supported by the recent 
finding that women with 2 ApoE4 alleles had significantly poorer memory and global 






identified in mouse models, with female mice expressing human E4 exhibiting 
increased pathology compared to males [20]. These differences include worsened 
cognitive impairment and decreased hippocampal presynaptic densities in females 
compared to their male counterparts [18]. 
The investigation into the relationship between ApoE and AD has largely 
focused on the role of ApoE as a lipid transport protein, including its role in 
metabolism and deposition of Aβ [21]. However, more recent study has investigated 
the role of ApoE4 in modulating vascular function and neuroinflammation. In the 
periphery the E4 variant is related to cardiovascular disease, particularly 
atherosclerosis [14, 15]. ApoE4 is also associated with altered cerebrovascular 
function. ApoE4 carriers exhibit altered cerebral blood flow (CBF) at a young age, and 
a greater decline in CBF during late adulthood [14, 22, 23]. Individuals with the E4 
allele also have an approximately 10% reduction in cerebral glucose metabolism [22, 
24]. The relationship between ApoE4 and cerebrovascular dysfunction has been 
furthered by findings in both in vivo and in vitro experimental models. ApoE4 
increases blood-brain barrier (BBB) permeability in mouse models [25]. ApoE4 was 
also associated with significantly reduced tight junction integrity and increased barrier 
permeability in vitro [26]. Both animal and human studies suggest that 
cerebrovascular dysfunction is present early in the pathological progression of AD 
[27, 28]. More recent findings highlight the relationship between ApoE4-mediated 
BBB breakdown, particularly in the hippocampus, and subsequent cognitive decline 
[29]. This suggests that one such mechanism whereby ApoE4 confers AD-related risk 
is through alterations in cerebrovascular function and integrity.  
ApoE4 is also being investigated for its role in modulating the innate immune 






disease and AD [30]. Analysis of human brain tissue shows that expression of 
proteins related to the regulation of inflammatory response is significantly correlated 
with ApoE genotype, with ApoE4 increasing the expression of inflammation-related 
mediators [31]. Both sex and ApoE status can modulate microglia phenotype [32]. 
Furthermore, microglia isolated from mice expressing human ApoE4 exhibit 
significantly increased production of pro-inflammatory cytokines and reactive nitrogen 
species (RNS) [33, 34]. Primary microglia expressing human ApoE4 display 
increased activation, including significantly increased secretion of tumor necrosis 
factor-α (TNF-α) and interleukin (IL)-6, along with induction of inducible nitric oxide 
synthase (iNOS) expression and activity [35]. ApoE4 is similarly related to 
significantly increased secretion of inflammatory factors in vitro in human and rat 
macrophages [36-38]. Neuroinflammation has been identified as a key aspect of AD 
pathology, and this neuroinflammatory response is primarily driven by microglia [39-
41]. Therefore, differential regulation of inflammatory process via microglia activation 
may be another way in which ApoE4 confers elevated risk for AD.  
Here, we sought to investigate the impact of ApoE4 on AD-related 
pathological processes in an animal model, with specific emphasis on markers related 
to cerebrovascular function and neuroinflammation. AD is believed to develop over a 
long time-course, with the cognitive impairment, protein aggregation, and 
neurodegeneration found towards the end of disease progress [42]. Therefore, mice 
expressing human ApoE4 were examined at 10 months of age, in order to explore a 
“middle-age” associated time point. Both male and female mice were included in the 
study in order to identify possible sex-specific changes in order to highlight possible 






associated risk. We hypothesized that ApoE4 will exert sex-specific detrimental 








Transgenic mice expressing human ApoE4 (Human APOE4 mouse: 
B6.129P2-Apoetm3(APOE*4)Mae N8, Model #1549-F, 1549-M) and wild-type 
controls (WT) (C57BL/6NTac, Model #B6-F, B6-M) were purchased from Taconic 
Biosciences, Inc. (Rensselaer, NY). Mice were maintained on normal chow (ENVIGO 
2020X, Huntingdon, UK) with water available ad libitum. At 10 months of age, mice 
were deeply anesthetized with ketamine (80 mg/kg) and xylazine (10mg/kg) 
administered I.P. and euthanized. All animal procedures were performed in 
accordance with NIH “Guide for the Care and Use of Laboratory Animals” and 
University of Rhode Island Animal Care and Use Committee (IACUC) guidelines. 
Western Blot 
Whole brains were removed post-sacrifice and the cerebellum was detached. 
Tissues were homogenized by sonication (Branson SX150 Sonifier ®, Branson 
Ultrasonics, Danbury, CT) in phosphate buffered saline (PBS) with 1X protease 
inhibitors. Homogenates were mixed with equal parts 2x Sample Buffer (4x Laemmli 
sample buffer with 10% 2-mercaptoethanol, 50% diH2O). Samples were then run on a 
4-20% Gel (NOVEX by Invitrogen, Carlsbad, CA) in 1x SDS-running buffer. Proteins 
were transferred to nitrocellulose membranes using iBlot2 Gel Transfer Device 
(ThermoFisher Scientific, Waltham, MA). After transfer, membranes were blocked 
using 5% bovine serum albumin (BSA) in 0.05% tris buffered saline with tween (TBS-
T) for 1 hr. Primary antibodies for this study include NOX4 (Sigma, MA; 1:1,000), 
iNOS (Abcam, MA; 1:250), eNOS (Abcam, MA; 1:500), GFAP (Abcam, MA; 
1:10,000), Iba1 (GeneTex, CA; 1:1,000), TNF-α (Novus Biologicals, CO; 1:500), IL-6 






(Cell Signaling Technologies, MA; 1:500), Synaptophysin (Cell Signaling 
Technologies, 1:1,000), and β-Actin (SantaCruz, CA; 1:10,000). Bound antibody was 
detected with infrared secondary antibodies (LiCOR, NE; 1:10,000), which was 
imaged on a LiCor Odyssey (LI-COR Biosciences, Lincoln, NE). Quantification of 
western blots was done in ImageJ. Values for each protein were normalized to β-
actin.  
Statistical Analysis 
All tests were performed in GraphPad Prism (GraphPad, CA). Data are 
represented as mean +/- standard error (SEM). Analysis was done by one-way 
analysis of variance (ANOVA) with Bonferroni multiple-comparisons follow-up. 







ApoE4 reduces the expression of tight junction proteins in a sex-specific manner 
Impaired BBB function leading to increased barrier permeability is associated 
with both AD and ApoE4 [29]. Tight junction proteins are crucial for the maintenance 
of BBB integrity, and reduced expression of junctional proteins, including claudin-5 
and occludin, have been identified in AD models [43]. Here, we assessed the 
expression of claudin-5 and occludin in wild-type and ApoE4 mice as a measure of 
tight junction formation and BBB integrity.  
Brains from 10-month-old male and female mice with ApoE4 or wild-type 
genotypes were collected, homogenized, and western blot was used to assess the 
expression of tight junction proteins. The expression of claudin-5 was significantly 
(p<0.05) increased in wild-type females compared to both wild-type and ApoE4 male 
mice. There was no difference in claudin-5 level between wild-type and ApoE4 males. 
In contrast, claudin-5 expression was lower in ApoE4 females compared to wild-type 
(p=0.0897) (Fig. 1A).  
The expression of occludin was significantly (p<0.05) decreased in ApoE4 
males compared to both wild-type males and ApoE4 females (Fig. 1B). There was no 
difference in occludin level between wild-type and ApoE4 females. These data 
suggest that ApoE4 reduces expression of tight junction proteins, thereby altering 
BBB integrity, in a sex-specific manner.  
The effect of ApoE4 on markers related to oxidative stress differs between males and 
females 
Oxidative stress is a key component of neuroinflammation in AD, marked by 
high amounts of reactive oxygen species (ROS) and reactive nitrogen species (RNS). 






and nitric oxide synthase (NOS), respectively. NOS family consists of several 
isoforms that function differently under physiologic and pathologic conditions. Here 
we examined the expression of both inducible NOS (iNOS) and endothelial NOS 
(eNOS). Brains from 10-month-old male and female mice with ApoE4 or wild-type 
genotypes were collected, homogenized, and western blot was used to assess the 
expression of NOX4, iNOS and eNOS  
There was no difference in the expression of NOX4 between male and female 
wild-type mice (Fig. 2A). The level of NOX expression in ApoE4 male was slightly, 
although not significantly, elevated compared to wild-type male. In contrast, female 
ApoE4 carriers showed decreased expression compared to wild-type mice. The 
expression of NOX4 was significantly (p<0.05) decreased in ApoE4 females 
compared to their male counterparts (Fig. 2A).  
There appears to be a gender difference in iNOS between male and female 
wild-type mice, with females displaying significantly (p<0.05) higher levels of this 
enzyme. Unlike NOX, there was no difference in iNOS between wild-type and ApoE4 
females. In male mice, iNOS was significantly (p<0.05) higher in ApoE4 animals 
compared to wild-type controls (Fig. 2B). eNOS expression was significantly (p<0.05) 
reduced in wild-type females compared to wild-type males. ApoE4 males also 
showed significantly (p<0.01) reduced expression of eNOS compared to wild-type 
males, while there was little difference in eNOS expressions between wild-type and 






ApoE4 differentially affects gliosis in males and females 
Another key component of the neuroinflammatory response found in AD is 
gliosis, the activation of glial species in the brain, particularly astrocytes and 
microglia. Glial fibrillary acidic protein (GFAP) gene activation and protein induction 
appear to play a critical role in astroglia cell activation (astrogliosis) following CNS 
injuries and neurodegeneration [44]. Similarly, ionized calcium binding adaptor 
protein1 (Iba1) has been used as an indicator of microgliosis [45]. Therefore, we 
investigated the expression of both GFAP and Iba1, as markers of astrocyte and 
microglia activation, respectively.  
Brains from 10-month-old male and female mice with ApoE4 or wild-type 
genotypes were collected, homogenized, and western blot was used to assess the 
expression of GFAP and Iba1.There was no difference in GFAP expression between 
wild-type and ApoE4 males. In contrast there was a significant (p<0.001) increase in 
GFAP expression in ApoE females compared to either wild-type females or ApoE 
males (Fig. 3A). 
The effect of ApoE4 on Iba1 expression appears to be sex-specific. The 
expression of Iba1 was significantly (p<0.01) increased in male ApoE4 compared to 
wild-type, while significantly (p<0.05) decreased in female ApoE4 compared to female 
wild-type animals. Additionally, there was a significant (p<0.01) difference in Iba1 
expression between ApoE4 females and males (Fig. 3B). These results indicate that 
the inflammatory processes may differ for ApoE4 males versus females, with females 
being driven by astrocytes and males being driven by microglia.  
ApoE4 exerts sex-specific effects on the expression of inflammatory cytokines 
Experimental and clinical evidence has demonstrated increased synthesis of 






inflammatory effects of ApoE4 we analyzed, by western blot, the expression of TNF-
α, IL-1β, and IL-6 in brain homogenates prepared from 10-month-old male and female 
mice with ApoE4 or wild-type genotypes (Fig. 4).  
Although there were no significant differences detected, expression of TNF-α 
trended down in male ApoE4 compared to wild-type and trended up in female ApoE 
compared to wild-type (Fig. 4A). The presence of the ApoE4 gene differentially 
affected expression of IL-1β based on sex. While ApoE4 males showed a slight 
decrease in IL-1β, relative to wild-type males, ApoE4 females showed a significant 
(p<0.01) increase in IL-1β compared to wild-type as well as ApoE4 males (Fig. 
4B).There was no significant difference in the expression of IL-6 between wild-type 
males and females. There was a sex-based pattern of expression of IL-6 in the 
presence of the ApoE4 gene. IL-6 was significantly (p<0.05) increased in ApoE4 
males compared to wild-type, while it was significantly (p<0.05) decreased in ApoE4 
females compared to their wild-type controls. Additionally, the expression of IL-6 was 
significantly (p<0.001) decreased in ApoE4 females compared to their male ApoE4 
counterparts (Fig. 4C).  
ApoE4 affects BDNF expression but not synaptic markers 
A key component of AD and other neurodegenerative disorders is neuronal 
cell death and the related loss of synaptic formation and function. To evaluate the 
ability of ApoE4 to indirectly affect neuronal viability, we evaluated expression of the 
neurotrophic protein brain-derived neurotrophic factor (BDNF) as well as two proteins 
(PSD-95 and synaptophysin) localized to the synapse that are related to synaptic 
formation.  
Brains from 10-month-old male and female mice with ApoE4 or wild-type 






expression of BDNF, PSD-95, and synaptophysin. The expression of BDNF was 
lower in wild-type female mice compared to wild-type male mice. BDNF expression 
was reduced in male ApoE4 mice compared to wild-type (p=0.0634). There were no 
differences in the expression of BDNF between ApoE4 females and either wild-type 
females or male ApoE4 animals (Fig. 5). The expression of both PSD-95 and 
synaptophysin was comparable between male and females and was not significantly 
altered by ApoE4 expression (Table 1). These data suggest that the loss of BDNF 
expression in ApoE4 mice does not contribute to a loss in synaptic proteins at 10 







The E4 allele of the lipid transport ApoE is the most significant genetic risk 
factor for late onset AD. While the exact mechanism behind the increased risk has not 
been identified, ApoE4 has been related to inflammation, vascular dysfunction, and 
neuron loss in AD [10]. There is sexual dimorphism in the risk for AD, and ApoE4 
confers a greater risk in females than males [18]. Here, we investigated the effect of 
ApoE4 on markers related to vascular function, inflammation, and oxidative stress in 
both male and female mice. These data from 10-month-old wild-type and ApoE4 male 
and female mice (considered middle-age, 38-47 years human age equivalent) 
indicate a sex-dependent difference in ApoE4-related effects on vascular function and 
inflammation.  
Cerebrovascular dysfunction and related BBB damage has been identified in 
AD pathology [27, 43]. Here, ApoE4 reduced the expression of TJ proteins in vivo. 
More specifically, ApoE4 was associated with decreased claudin-5 in females and 
decreased occludin in males, suggesting that ApoE4 modulate TJ formation and 
therefore barrier permeability in a sex-specific fashion.  
Alterations in eNOS also likely indicate cerebrovascular dysfunction. The 
enzyme eNOS is thought to have a role in regulating vasodilation and BBB function. 
Here, eNOS showed significantly lower levels in wild-type female and both ApoE4 
male and females compared to WT males. NO produced by eNOS is known to have 
vasoregulatory and neuroprotective functions [47-49]. Additionally, a significant 
negative correlation between eNOS capillary expression and neurofibrillary tangle 
and senile plaque burden has been reported in AD brains [50]. On the other hand, 
iNOS expression was upregulated in both wild-type and ApoE4 females. Unlike 






inflammatory processes in a number of cell types [51]. Deficiency of iNOS has been 
shown to protect AD-like mice from premature mortality, cerebral plaque formation, 
increased β-amyloid levels, protein tyrosine nitration, astrocytosis, and microgliosis 
[52]. In opposition to the iNOS findings, NOX4 expression levels were significantly 
lower in ApoE4 female compared to ApoE4 males. These findings may suggest that 
ApoE4-related dysfunction is largely driven by nitrosative processes rather than 
oxidative in females. Together, these data suggest ApoE4 promotes vascular 
dysfunction, nitrosative stress, and related inflammatory processes in females.  
Similar sex-dependent differences were found in expression levels of 
proinflammatory cytokines. IL-6 expression was higher in ApoE4 males than in 
females, while IL-1β expression was significantly higher in females compared to 
males. At low concentrations, IL-1β increased GFAP expression in a dose-and time-
dependent manner. Additionally, IL-1β activates NF-κβ and increases iNOS and 
pERK expression [53]. Here, we found that GFAP expression was also significantly 
higher in ApoE4 females, congruent with the IL-1β findings. These data indicate that 
IL-1β may drive the astrogliosis and nitrosative stress found in ApoE4 female mice. 
High levels of GFAP have previously been studied in association with AD pathology. 
Impaired spatial memory retention was found in female mice expressing ApoE4 
compared to those expressing ApoE3 in astrocytes or lacking ApoE has been 
reported [54]. This highlights a potential role for GFAP in ApoE4 related cognitive 
dysfunction, and may indicate one such mechanism whereby ApoE4 exerts increased 
risk in females.  
Similar to females, male ApoE4 mice exhibited reduced expression of eNOS 
compared to WT, indicating likely cerebrovascular dysfunction. However, male ApoE4 






females, ApoE4 male mice showed significantly increased expression of both Iba1 
and IL-6 compared to WT males, indicating enhanced microglial activation. Microglia 
have an augmented inflammatory response in the aged brain, and IL-6 signaling 
throughout aging may enhance this response [55]. Transgenic mice that overexpress 
IL-6 in the brain show neurodegeneration, demyelination, and decreased 
hippocampal LTP. Additionally, these mice exhibit increased microglia number and a 
progressive microglia activation, related to neurodegeneration and learning 
impairment [56]. Moreover, IL-6 stimulated microglia increase production of 
complement C3, an inflammatory mediator implicated in neuron loss and synapse 
engulfment in the AD brain [56]. Finally, a mutation in the IL-6 surface receptor, 
related to increased IL-6 response genes in AD, has been associated with an earlier 
age of onset in AD patients with the ApoE4 allele [57]. Taken together, these findings 
suggest that enhanced IL-6/microglia signaling is a driver in ApoE4-related 
inflammatory changes and related memory impairments in males. The results of this 
study implicate sex-specific inflammatory processes in the brain’s response to ApoE4.  
A main pathological feature of Alzheimer’s is neuron loss, indicated by 
substantial reduction in gray matter volume found in the AD brain [39]. AD pathology, 
including cognitive impairment, is the result of this neuron death and related synapse 
loss. Additionally, reduced levels of neurotrophic factors, including BDNF, have been 
identified in human AD [58, 59]. Compared with aged controls, BDNF expression 
levels were found decreased in hippocampus and frontal, parietal, and temporal 
cortex of AD post-mortem samples [58]. AD is believed to be a disease that develops 
over a long time-course, with neurodegeneration and related cognitive impairment 
belived to occur late in disease progress [42]. Though neuroinflammatory changes in 






synaptic proteins PSD-95 and synaptophysin were observed. These data indicate 
there is little to no significant neurodegeneration in 10-month-old ApoE4 animals, 
highlighting the idea that vascular and inflammatory changes likely occur before 
neurodegeneration in the pathological progression of AD.  Future studies may benefit 
from sampling animals at different time points, in order to develop an understanding 
of the longitudinal changes that occur as a result of ApoE4 in the brain.  
In order to identify if cardiovascular risk factors injure the vasculature in 
ApoE4 mice triggering NOX and NOS which drive vascular activation and impaired 
cognition, additional future studies should investigate the role that these two 
mediators play in the vascular activation and inflammation found to be associated 
with ApoE4 in vivo. This may be done by investigating ApoE4-related pathology in 
iNOS and NOX knockout mouse models. Based on the results of this study, we would 
expect knockout of NOS and NOX to modulate the pro-inflammatory response to 
ApoE4 found in female and male mice, respectively. Overall, our findings highlight 
that ApoE4 exerts sex-specific effects on markers of inflammation and vascular 
dysfunction in males and females. In particular, female mice expressing human 
ApoE4 exhibited eNOS-mediated vascular dysfunction as well as pro-inflammatory 
pathology indicated by increases in iNOS, IL-1β, and GFAP. On the other hand, pro-
inflammatory alterations in male ApoE4 mice were highlighted by increases in Iba1 
and IL-6. Additionally, the changes in males were less robust than females. 
Altogether, these findings highlight possibly mechanisms whereby the ApoE4 allele 
increases the risk for AD, and shed light on how ApoE4 may differentially affect males 








Figure 1 | In vivo expression of tight-junction proteins in ApoE4 vs. Wild Type 
mice. Brains from 10-month-old male and female mice with ApoE4 or Wild Type 
genotype were collected and homogenized. Western blot was used to assess the 
expression of tight junction proteins: A) Claudin-5 and B) Occludin. N=3, * denotes 
significance compared to the group of the same sex and opposite genotype 
(*p<0.05), # denotes significance compared to the group from the opposite sex of the 








Figure 2 | In vivo expression of oxidative stress-related proteins in ApoE4 vs. 
Wild Type mice. Brains from 10-month-old male and female mice with ApoE4 or Wild 
Type genotype were collected and homogenized. Western blot was used to assess 
the expression of oxidative-stress related proteins: A) NOX4, B) iNOS, and C) eNOS. 
N=3, * denotes significance compared to the group of the same sex and opposite 
genotype (*p<0.05, **p<0.01), # denotes significance compared to the group from the 








Figure 3 | Expression of gliosis markers in vivo in ApoE4 vs. Wild Type mice.  
Brains from 10-month-old male and female mice with the ApoE4 or Wild Type 
genotype were collected and homogenized. Western blot was used to assess the 
expression of markers of astrogliosis and microgliosis: A) GFAP and B) Iba1. N=3, * 
denotes significance compared to the group of the same sex and opposite genotype 
(***p<0.001), # denotes significance compared to the group from the opposite sex of 








Figure 4 | Expression of inflammatory cytokines in vivo in ApoE4 vs. Wild Type 
mice. Brains from 10-month-old male and female mice with the ApoE4 or Wild Type 
genotype were collected and homogenized. Western blot was used to assess the 
expression of inflammatory cytokines: A) TNF-α, B) IL-1β, and C) IL-6. N=3, * 
denotes significance compared to the group of the same sex and opposite genotype 
(*p<0.05), # denotes significance compared to the group from the opposite sex of the 








Figure 5 | Expression of BDNF in vivo in the brain of ApoE4 vs. Wild Type mice.  
Brains from 10-month-old male and female mice with the ApoE4 or Wild Type 
genotype were collected and homogenized. Western blot was used to assess the 








Table 1 | Expression of synaptic proteins in ApoE4 and Wild Type mice in vivo. 
Brains from 10-month-old male and female mice with the ApoE4 or Wild Type 
genotype were collected and homogenized. Western blot was used to assess the 
expression of the synaptic proteins PSD-95 and synaptophysin (SYP). Protein 












PSD-95 0.8776±0.028 0.9061±0.089 0.9513±0.025 0.9285±0.048 p=0.7949 
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The societal burden of Alzheimer’s disease (AD) is staggering, with current estimates 
suggesting that 50 million people world-wide have AD. Identification of new 
therapeutic targets is a critical barrier to the development of disease-modifying 
therapies. A large body of data implicates vascular pathology and cardiovascular risk 
factors in the development of AD, indicating that there are likely shared pathological 
mediators. Inflammation plays a role in both cardiovascular disease and AD, and 
recent evidence has implicated elements of the coagulation system in the regulation 
of inflammation. In particular, the multifunctional serine protease thrombin has been 
found to act as a mediator of vascular dysfunction and inflammation in both the 
periphery and the central nervous system. In the periphery, thrombin contributes to 
the development of cardiovascular disease, including atherosclerosis and diabetes, 
by inducing endothelial dysfunction and related inflammation. In the brain, thrombin 
has been found to act on endothelial cells of the blood-brain barrier, microglia, 
astrocytes, and neurons in a manner that promotes vascular dysfunction, 
inflammation, and neurodegeneration. Thrombin is elevated in the AD brain, and 
thrombin signaling has been linked to both tau and amyloid beta, pathological 
hallmarks of the disease. In AD mice models, inhibiting thrombin preserves cognition 
and endothelial function and reduces neuroinflammation. Evidence linking atrial 
fibrillation with AD and dementia indicates that anticoagulant therapy may reduce the 
risk of dementia, with targeting thrombin shown to be particularly effective. It is time 
for “outside-the-box” thinking about how vascular risk factors, such as atherosclerosis 
and diabetes, as well as the coagulation and inflammatory pathways interact to 
promote increased AD risk. In this review, we present evidence that thrombin is a 






could target multiple points of AD pathology, including neurodegeneration, vascular 
activation, and neuroinflammation. The urgent need for disease-modifying drugs in 
AD demands new thinking about disease pathogenesis and an exploration of novel 
drug targets, we propose that thrombin inhibition is an innovative tactic in the 








The societal burden of Alzheimer’s disease (AD) is staggering, with current 
estimates suggesting that 5.8 million Americans and 50 million people worldwide 
have AD ("2019 Alzheimer's disease facts and figures," 2019). Identification of new 
therapeutic targets is a critical barrier to our ability to develop a disease-modifying 
therapy for this devastating disease. A large body of data implicates vascular 
pathology and cardiovascular risk factors, such as atherosclerosis and diabetes, in 
the development of AD. Though the mechanisms whereby these risk factors 
contribute to pathological processes in the AD brain have not been defined fully, it 
has been suggested that inflammation plays a key role in both cardiovascular disease 
and AD (Grammas, 2011). It is clear that a better understanding of the relationship(s) 
among cardiovascular risk factors, inflammation, and neurodegeneration has the 
potential to reveal novel therapeutic targets in the battle against AD.  
Recently, a number of laboratories have provided evidence that certain 
elements of the coagulation cascade may initiate and/or support inflammation in the 
brain (Davalos & Akassoglou, 2012; De Luca et al., 2017; Göbel et al., 2018). The 
proinflammatory properties of the protein fibrin have attracted particular attention 
(reviewed in (Cortes-Canteli et al., 2012; Petersen et al., 2018)). Fibrin increases 
expression of a number of inflammatory and oxidative mediators, activates glial cells, 
and disrupts the blood-brain barrier (BBB). Another potentially important protein 
related to both coagulation and inflammation is thrombin. Thrombin is widely 
appreciated for its contribution to fibrin formation and platelet aggregation in response 
to vascular injury. Importantly, thrombin is also a pleiotropic enzyme that is capable of 
triggering a large and diverse number of cellular events through receptor-mediated 






thrombin and the thrombin receptor PAR-1 are elevated in AD (Krenzlin et al., 2016; 
Sokolova & Reiser, 2008) and thrombin expression is increased in brain microvessels 
collected from AD patients (Grammas et al., 2006). As we discuss below, thrombin 
can act in both a paracrine and autocrine manner to stimulate a noxious feed-forward 
cycle that likely contributes to neuroinflammation in the AD brain. The evidence 
summarized herein suggests that thrombin is a convergence point for AD risk factors 
and that thrombin-based therapeutics might target multiple points of AD pathology, 
including neurodegeneration, vascular activation, and neuroinflammation. We will 
present evidence that supports the hypothesis that thrombin could be a heretofore 







Coagulation and inflammation: Functionally linked processes 
Close integration and extensive crosstalk between coagulation and 
inflammation pathways are critical to the body’s response to injury. Both processes 
utilize numerous bioactive mediators and cellular effectors that interact in a 
coordinated manner. Inflammatory proteins, such as cytokines, play a central role in 
the activation of coagulation. Meanwhile major coagulation factors, such as tissue 
factor, fibrinogen, and thrombin, are drivers of inflammation. Under normal 
physiological conditions these intertwined systems work in homeostatic balance, but 
dysregulation of this crosstalk likely contributes to cellular injury and disease 
pathogenesis.  
Effect of cytokines on coagulation 
Cytokines, particularly interleukin (IL)-6, tumor necrosis factor-α (TNF-α), and 
IL-1β, stimulate procoagulant effects both directly and indirectly. These proteins 
initiate the extrinsic coagulation pathway through up-regulation and activation of 
tissue factor (Nawroth & Stern, 1986; Witkowski et al., 2016). Blocking tissue factor 
greatly inhibits inflammation-induced thrombosis, and inhibition of IL-6 specifically 
blocks tissue factor-dependent thrombin generation (Levi et al., 1997). Cytokines, 
especially TNF-α, can also initiate inflammation-mediated platelet activation and 
clumping in the blood (Page et al., 2018). Inflammatory cytokines can inhibit the 
anticoagulant feedback pathways, resulting in increased thrombin and fibrin 
production (Levi & van der Poll, 2005). Both TNF-α and IL-1β can reduce activated 
protein C (APC) via down-regulation of thrombomodulin, an important cofactor for 
APC’s anti-inflammatory and anti-coagulant activity (Nawroth & Stern, 1986).  






Tissue factor, the main driver of the extrinsic coagulation pathway, can induce 
proinflammatory effects. This includes increases in the production of inflammatory 
cytokines, adhesion molecules, chemokines, and growth factors. These 
proinflammatory effects are largely mediated through tissue factor-activation of the 
protease thrombin (see below). Fibrin is the primary end-product of the coagulation 
system, but it also has proinflammatory characteristics. Fibrinogen and fibrin both 
have been shown to induce leukocyte migration, and directly modulate the 
inflammatory response of both leukocytes and endothelial cells. Fibrin induces the 
expression of several inflammatory cytokines and chemokines and increases the 
production of reactive oxygen species (ROS) (Jennewein et al., 2011). Similarly, fibrin 
has been shown to have extensive proinflammatory effects within the central nervous 
system (CNS), including activation of glia and disruption of blood-brain barrier (BBB) 
function (Petersen et al., 2018). Fibrinogen activates microglia in a CD11b-dependent 
manner; this activation is related to perivascular clustering, axonal degeneration, 
spine elimination, and cognitive impairment in animal models (Davalos et al., 2012; 
Merlini et al., 2019). Finally, the coagulation and immune systems are directly linked 







Thrombin is a key mediator of coagulation and inflammation via proteolytic and 
receptor-mediated mechanisms 
The coagulation cascade consists of the intrinsic and extrinsic pathways, and 
thrombin is a key mediator in both. The extrinsic system is activated by tissue factor, 
which is found in the subendothelial surface and is only introduced to the blood 
following injury. Tissue factor in the blood complexes with factor VIIIa to initiate the 
cascade that will eventually lead to the formation of thrombin and the cleavage of 
fibrinogen to fibrin (Witkowski et al., 2016). The intrinsic system is activated by factor 
XII, which initiates a cascade that will lead to the production of thrombin via factors X 
and V (Palta et al., 2014). The activation of thrombin will also activate a positive 
feedback-loop which will continue to drive the generation of thrombin. Together, these 
systems work to increase the amount of active thrombin in the blood, which will in turn 
increase the insoluble fibrin available to form a clot at the site of damage. 
As noted above, thrombin is a multifunctional protease that can initiate many 
cellular events through action at and activation of PARs. PARs are a unique class of 
G-protein-coupled receptors due to their unusual tethered-ligand mechanism of 
activation (Coughlin, 2000). Thrombin is responsible for enzymatic cleavage of the 
PAR N-terminus to expose a tethered ligand that intramolecularly activates the 
receptor. Activation of PARs by thrombin affects a multitude of functions throughout 
the body, including the regulation of platelet activation, cell adhesion, cell migration, 
angiogenesis, and inflammation (Coughlin, 2005; Kalz et al., 2014). 
The vasculature is a critical nexus for the proinflammatory actions of thrombin  
Much of thrombin’s proinflammatory activity is likely due to its numerous 
effects on vascular endothelial cells. Thrombin acts on endothelial cells to stimulate 






stimulation of human umbilical vein endothelial cells (HUVECs) produces changes in 
gene expression related to inflammation, apoptosis, and matrix integrity (Okada et al., 
2006). Thrombin-treated HUVECs exhibit increased expression of intracellular 
adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) and 
a related increase in monocyte adhesion (Kaplanski et al., 1998). In human aortic 
endothelial cells (HAECs), thrombin and high-glucose co-treatment produces 
increases in the expression of NADPH oxidase (NOX), inflammatory cytokines, and 
altered adhesion (Wang et al., 2014). Cultured endothelial cells exposed to thrombin 
release von Willebrand factor, express P-selectin at the plasma membrane, and 
produce chemokines thought to trigger the binding of platelets and leukocytes to 
endothelial surface (Collins et al., 1993). Thrombin can affect vessel diameter, alter 
endothelial cell shape, and increase permeability of the endothelial monolayer. 
Endothelial cells can both release thrombin and respond to this protein via 
functionally active thrombin receptors (PAR-1 and PAR-3). Thrombin causes 
endothelial activation and enhanced expression and/or release of many 
proinflammatory proteins including monocyte chemoattractant protein-1 (MCP-1), 
ICAM-1, IL-1, IL-6, and IL-8, which in turn can injure endothelial cells leading to 
increased release of thrombin (Colotta et al., 1994; Ishibashi et al., 2014; Marin et al., 
2001; Miho et al., 2005; Okada et al., 2006; Rahman et al., 2002; X. Yin et al., 2010). 
Thus, thrombin can act in both a paracrine and autocrine manner stimulating a 






Thrombin contributes to the development of Alzheimer’s risk factors: 
atherosclerosis and diabetes 
Given thrombin’s effect on endothelial cells, it is not surprising that thrombin 
has been implicated in the pathogenesis of atherosclerosis. Thrombin has been 
widely studied for its role in the pathology of atherosclerosis, a progressive and 
chronic inflammatory vascular disorder (Jaberi et al., 2019; Kalz et al., 2014). A role 
for thrombin in the development of atherosclerosis is suggested by the observation 
that elevated levels of thrombin and the thrombin receptor PAR are found around 
atherosclerotic plaques, and that thrombin formation is correlated with disease 
severity in coronary atherosclerosis (Borissoff et al., 2012). Thrombin facilitates 
recruitment of circulating monocytes to atherosclerosis plaques by increasing 
expression of MCP-1, ICAM-1 and VCAM-1 (Colotta et al., 1994; Kalz et al., 2014; 
Minami et al., 2004). The importance of thrombin is further highlighted by the finding 
that thrombomodulin, which inhibits thrombin by binding to it, diminishes thrombin-
induced endothelial cell dysfunction in atherosclerosis (Wei et al., 2011). Thrombin 
produces damage to endothelial cell barriers causing leakiness and associated 
leukocyte migration (Kalz et al., 2014). Thrombin inhibition has been shown to 
decrease ROS production, improve endothelial cell and barrier function, and 
attenuate atherosclerotic plaque formation (I. O. Lee et al., 2012). 
Thrombin activity can influence onset, progression, and qualitative properties 
of atherosclerotic plaques. In atherosclerotic models, increases in thrombin have 
been found to be associated with increases in inflammation, angiogenesis, and cell 
proliferation (Kalz et al., 2014; ten Cate, 2012). Genetic reduction of thrombin in 
APOE-/- mice diminished atherosclerosis severity (Borissoff et al., 2013). Studies 






atherosclerosis-related pathology in animal models treated with thrombin inhibitors 
(Palekar et al., 2016; Pingel et al., 2014; Preusch et al., 2015; Wei et al., 2011). On 
the other hand, genetic manipulations resulting in elevated thrombin levels produce 
exacerbated atherosclerosis-related pathology (Borissoff et al., 2013). These findings 
illustrate a causative role for thrombin in the development of atherosclerosis-related 
pathology and inflammation, largely through thrombin’s endothelial cell-mediated 
effects.  
Hyperglycemia, characteristic of Type 2 diabetes mellitus (T2DM), enhances 
thrombin generation and promotes a hypercoagulable state and high oxidative stress 
(Aoki et al., 1996; Chapman, 2013; Undas et al., 2008). Elevated thrombin activity 
has been linked with endothelial dysfunction in diabetes, including vascular 
inflammation and increased ROS production (Paneni et al., 2013). One mechanism 
whereby thrombin promotes diabetic oxidative stress is via calcium-mediated 
intracellular signaling pathways that regulate the transcription factor KLF14 and PLK1 
kinase pathways, resulting in increased ROS production (Hao et al., 2018). 
Exogenous thrombin treatment has been shown to exacerbate pathology in 
experimental models of diabetes. In a mouse model of diabetes, thrombin treatment 
of pericytes result in increased barrier permeability, decreased expression of tight 
junction proteins, and increased expression of inflammatory cytokines (Machida et al., 
2017). Induction of diabetes by streptozotocin (STZ) in mice increases the expression 
of PAR-1, PAR-3, and PAR-4 in the aorta. STZ-induced diabetic mice show 
impairment of endothelial function, while the administration of dabigatran etexilate, a 
direct thrombin inhibitor, significantly attenuates this endothelial dysfunction 






Patients with T2DM show increased blood thrombin levels correlated with the 
patient’s level of albuminuria, an indicator of cardiovascular morbidity and mortality in 
patients with T2DM. This suggests that thrombin may play a role in the development 
of macrovascular disease (Ay et al., 2012). Thrombin-related pathways have also 
been implicated in diabetic microvascular injury and retinopathy. Samples taken from 
diabetic retinopathy patients show elevated expression of thrombin and PAR-1; 
similar trends are found in samples from a rat model of diabetes (Abu El-Asrar et al., 
2016). Obesity promotes a chronic inflammatory and hypercoagulable state that 
drives cardiovascular disease and T2DM. Recent studies have suggested a link 
between the thrombin/fibrin(ogen) axis and obesity (Kopec et al., 2017). In a high fat 
animal model, treatment with the direct thrombin inhibitor dabigatran etexilate 
ameliorates the development of obesity and severity of associated sequelae (Kopec 







Thrombin causes vascular dysfunction and promotes inflammation in the brain.  
Largely due to its proinflammatory effects on endothelial cells, thrombin has 
an important role in the pathology of various peripheral vascular diseases, including 
atherosclerosis and diabetes. Thrombin may similarly act as a pathological mediator 
in the central nervous system, through effects on the endothelial cells of the blood-
brain barrier. 
Effects of thrombin on the blood-brain barrier  
Consistent with its ability to cause endothelial injury in the periphery, thrombin 
has been found to be involved in instances of damage and dysfunction to the brain 
endothelial cells of the BBB. Treatment of rat brain endothelial cells causes 
endothelial dysfunction characterized by increased production of ROS, nitric oxide 
(NO), inflammatory cytokines, and chemokines (Brailoiu et al., 2017). In human brain 
endothelial cells, thrombin treatment induces an inflammatory phenotype resulting in 
increased ICAM-1, VCAM-1 and increased mRNA expression for CXC chemokines 
(chemotactic for neutrophils) CXCL1 (GRO-alpha), CXCL2 (GRO-beta), CXCL8 (IL-
8), and CXCL10 (IP-10) (Alabanza & Bynoe, 2012). Thrombin also increases F-actin 
stress fibers, disrupts tight junctions, and increases barrier permeability (Brailoiu et 
al., 2017). More specifically, thrombin has been found to alter barrier permeability by 
inducing microtubule disassembly (Birukova et al., 2004) and activating Src kinase 
(Liu et al., 2010). Treatment with a direct thrombin inhibitor reduces the ROS 
generation and expression of proinflammatory cytokines by cultured brain endothelial 
cells in response to hypoxia, indicating a mediating role for thrombin in the 
proinflammatory response of brain endothelial cells (Tripathy et al., 2013). 
We have previously demonstrated that thrombin message is highly expressed in 






2010) Similarly, Western blot analysis of microvessels shows that the thrombin 
protein is highly expressed in AD- but not control-derived microvessels (Grammas et 
al., 2006). Furthermore, injuring brain endothelial cells in vitro with oxidant stress 
(sodium nitroprusside) or an inflammatory cocktail (IL-1β, IL-6, TNF-α, 
lipopolysaccharide (LPS), interferon (IFN)-γ) results in thrombin release (Grammas et 
al., 2004). Since brain endothelial cells can both synthesize and respond to thrombin, 
it could function as an autocrine factor at the BBB. The importance of findings 
regarding the effects of thrombin on the cells of the BBB is two-fold. Directly, thrombin 
damage to the BBB increases permeability and may allow damaging substances, 
including thrombin and other inflammatory mediators from the blood, to enter the 
brain. Indirectly, these injured brain endothelial cells can produce their own thrombin 
into the brain, where it may have untoward effects on microglia, astrocytes and 
neurons (See Figure 1). 
Neuroinflammatory effects of thrombin on microglia and astrocytes  
The response of microglia to thrombin encompasses a number of processes that 
contribute to microglia activation and/or apoptosis. In the microglial cell line BV2, 
thrombin induces IL-1β release (C. Han et al., 2019). Thrombin has also been shown 
to stimulate a proinflammatory phenotype in microglia, characterized by increases in 
ROS, NO, and cytokine production (Huang et al., 2008; D. Y. Lee et al., 2006; Yang 
et al., 2015; Ye et al., 2017). PAR-1 activation was found to participate in activation of 
microglia, indicated by up-regulation of microglial CD40 and TNF-α production (Suo 
et al., 2002). Thrombin, via the TNF-α/TNFR-dependent pathway, downregulates 
expression of the mRNA species miR-181c, which in turn promotes nuclear factor 
(NF)-κB activity, and upregulates NF-κB target gene expression as well as increasing 






2017). BV2 cells treated with thrombin show an increase in ROS and the nucleotide-
binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3) 
inflammasome, a component of the innate immune system, which is associated with a 
wide range of human CNS disorders (Ye et al., 2017). 
Astrocytes show a similar shift towards a pro-inflammatory phenotype in 
response to thrombin. In rat brain astrocytes, thrombin induces matrix 
metalloproteinase (MMP)-9 expression and promotes cell migration via activation of 
the c-Src/Jak2/PDGFR/PI3K/Akt/PKCδ pathway (Lin et al., 2013). Thrombin exposure 
can disrupt glutamate transport in astrocytes and modulate stellation, indicating an 
alteration in function (Cavanaugh et al., 1990; C. Piao et al., 2015). Thrombin 
treatment in vivo resulted in increased glial fibrillary acidic protein (GFAP) expression 








Thrombin an important mediator of neurotoxicity and neurodegenerative 
diseases 
The multifunctional protease thrombin causes neuronal cell death both in vitro 
and in vivo. The neurotoxic effects of thrombin are orchestrated by multiple pathways. 
In vitro, thrombin-induced neurotoxicity involves activation of PAR-1, followed by 
RhoA activation and cell cycle re-entry. In neurons treated with thrombin, cyclin D1 
and E (early G1 cyclins) and the cyclin dependent kinase, cdk4, are activated and 
that these events lead to upregulation of the pro-apoptotic protein Bim and apoptosis 
(Rao et al., 2007). Additionally, thrombin has been demonstrated to cause a rapid 
influx of calcium in neurons leading to neuronal cell death (Smirnova et al., 1998). 
Delivery of thrombin directly into the brain by intracerebral injection causes significant 
neuropathology, such as enlargement of cerebral ventricles, an increased number of 
TUNEL-positive cells, astrogliosis, and an increase in the immunoreactivity for 
phosphorylated neurofilament and apolipoprotein-E (ApoE) fragments, as well as 
cognitive impairments including deficits in reference memory and an increase in task 
latency (Mhatre et al., 2004). The large body of data indicating thrombin is an 
important mediator of neuroinflammation and neurotoxicity supports the idea that this 
protein is critically involved in pathological processes that contribute to the 
development of neurodegenerative diseases including multiple sclerosis (MS), 
amyolaterotrophic sclerosis (ALS), ischemia, traumatic brain injury (TBI), Parkinson’s 
disease (PD) and AD.  
Alterations in coagulation-related proteins have been indicated in motor-
associated degenerative disorders. Both prothrombin and factor X are elevated in MS 
(Gobel et al., 2016). Proteomic analysis of chronic active MS lesions identified several 






cascade and MS pathology (M. H. Han et al., 2008). In experimental autoimmune 
encephalomyelitis (EAE), an experimental model of MS, thrombin activity precedes 
onset of neurological signs, increases at disease peak, and correlates with fibrin 
deposition, microglial activation, demyelination, axonal damage, and clinical severity 
(Davalos et al., 2014). The potential pathological significance of coagulation factors in 
neurological disease is underscored by the finding that the diminution of fibrin, the 
end product of thrombin’s proteolysis, either genetically or using anticoagulants, 
significantly reduces neurological signs, inflammation, and axonal damage in EAE 
(Davalos & Akassoglou, 2012). Additionally, thrombin has been linked to changes in 
interneuron calcium signaling and enhanced thrombospondin release in ALS (De 
Luca et al., 2017).  
Thrombin has been extensively studied for its role in the response to ischemia 
(Matsuoka & Hamada, 2002). Thrombin was found to mediate neurovascular injury 
during ischemia (B. Chen et al., 2010), and increased thrombin activity was 
associated with subsequent neuronal damage in a model of acute focal ischemia (B. 
Chen et al., 2012). While high concentrations of thrombin seem to be neurotoxic, low 
concentrations of thrombin (.01 U/mL) were found to protect against neuronal death 
in cellular and animal models of ischemia (Striggow et al., 2000). Increases in 
thrombin have also been associated with traumatic brain injury (TBI). Alterations in 
BBB permeability have been found following TBI (Hay et al., 2015; Korn et al., 2005). 
In a model of TBI, BBB damage due to the injury was found to induce increases in 
thrombin (C. S. Piao et al., 2019).  
A role for thrombin has also been identified in PD-related pathology. More 
specifically, thrombin-induced activation of microglia in the midbrain has been directly 






PAR-1 is upregulated in the brains of patients with PD (Ishida et al., 2006; Sokolova 
& Reiser, 2008). Recently, our lab has identified that dabigatran treatment improved 
motor deficits and reduced markers of oxidative stress in a Drosophila melanogaster 
model of PD (unpublished findings).  
A role for thrombin in PD is further indicated by the finding that treatment with 
a direct thrombin inhibitor is neuroprotective in a rotenone-induced PD rodent model 
(Kandil et al., 2018). Finally, mice deficient in PAR-1 are protected against 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced toxicity which causes PD-like 







A case for thrombin as a driver of neurodegeneration and vascular activation in 
Alzheimer’s disease 
Thrombin is associated with typical hallmarks of AD-related pathology. 
Thrombin has been detected in senile plaques and in neurofibrillary tangles 
characteristic of this disease (Akiyama et al., 1992; Arai et al., 2006), and levels of 
both thrombin and the thrombin receptor PAR-1 are elevated in AD (Krenzlin et al., 
2016; Sokolova & Reiser, 2008). Traumatic brain injury, a condition in which neurons 
are exposed to high thrombin levels, is associated with an increased incidence of AD 
(Mortimer et al., 1991; Nemetz et al., 1999). Thrombin may also contribute to ApoE-
associated pathology in AD. Intracerebral administration of thrombin to rodents 
increases ApoE levels in the hippocampus and results in neuronal injury and 
cognitive deficits (Mhatre et al., 2006). The 22 kDa N-terminal thrombin-cleavage 
fragment of ApoE is highly neurotoxic and could contribute to ApoE-associated AD 
pathology (Tolar et al., 1997). Persistent thrombin signaling induces tau aggregation 
and related hippocampal degeneration (Arai et al., 2005; Suo et al., 2003). Thrombin 
induces secretion of amyloid precursor protein (APP) in endothelial cells in vitro 
(Ciallella et al., 1999) and may be involved in altered processing of APP into 
fragments that are found in amyloid plaques of AD brains (Chong et al., 1994; 
Ciallella et al., 1999; Igarashi et al., 1992). Aβ promotes thrombin generation through 
factor XII-mediated factor XI activation (Zamolodchikov et al., 2016). In this regard, 
depletion of factor XII ameliorates brain pathology and cognitive impairment in AD 
mice. Additionally, the factor XII-initiated contact system, of which thrombin is a key 








Vascular activation: A novel pathway in AD: A role for thrombin  
Microvessels isolated from the brains of AD patients overexpress a diverse 
array of neurotoxic and inflammatory proteins (Grammas & Ovase, 2001; Grammas 
et al., 2006). Expression of these diverse mediators is consistent with the process of 
vascular activation and reflects the transition of endothelial cells from a quiescent to a 
highly synthetic phenotype. A similar pattern of vascular activation has been identified 
in transgenic AD animal models. Vascular activation in the AD brain has deleterious 
consequences for neuronal viability, as many vascular-derived factors are neurotoxic. 
The idea that vascular activation contributes to pathogenic events in the AD brain is 
strongly supported by pre-clinical studies in two AD mouse models where treatment 
with a vascular activation inhibitor reduced vascular-derived neuroinflammation and 
improved cognitive performance (Grammas et al., 2014).  
Several lines of evidence support the idea that the cerebral vasculature is a 
convergence point for both the expression of thrombin as well as thrombin-mediated 
effects that contribute to neuroinflammation and neuronal injury in AD. While the 
majority of thrombin is produced in the liver, extrahepatic sources of locally generated 
thrombin, including in the brain, have been documented (Deschepper et al., 1991). 
Although not widely appreciated, evidence suggests the cerebrovasculature is an 
important source of thrombin in AD. Immunoreactivity for the major brain thrombin 
inhibitor, protease nexin-1, is found to be significantly decreased in AD brains, 
particularly around blood vessels, suggesting vascular release of thrombin (Vaughan 
et al., 1994). As previously stated, thrombin mRNA and protein are expressed in brain 
microvessels from AD patients but not detectable in brain microvessels isolated from 
age-matched control brains (Grammas et al., 2006; X. Yin et al., 2010). It is not 






experiments with brain endothelial cells have shown that injuring these cells causes 
release of thrombin (Grammas et al., 2004). Because brain endothelial cells not only 
produce thrombin in response to injury but respond to thrombin with a robust 
inflammatory response, thrombin is likely a key mediator of cerebrovascular activation 
in AD. 
The release of vascular-derived inflammatory proteins could stimulate/activate 
neighboring glial cells, both microglia and astrocytes, to release inflammatory proteins 
as well as noxious ROS and proteases. This noxious, neurotoxic cycle could be 
augmented by vascular-derived thrombin. In addition to thrombin's inflammatory 
effects on brain endothelia, thrombin could contribute to deleterious and self-
perpetuating neuroinflammation via induction of proinflammatory cytokines including 
IL-1β, IL-6, TNF-α in microglia and astrocytes (M. S. Choi et al., 2008; S. H. Choi et 
al., 2003; Huang et al., 2008; D. Y. Lee et al., 2006). A recent study in the TgCRND8 
AD mouse showed that long-term treatment with the thrombin inhibitor dabigatran 
preserved cognition, cerebral perfusion, and BBB function, and ameliorated 
neuroinflammation and amyloid deposition (Cortes-Canteli et al., 2019). 
Administration of dabigatran to transgenic AD mice diminishes ROS levels in brain 
and reduces cerebrovascular expression of inflammatory proteins, further supporting 
an important role for thrombin as a mediator of neuroinflammation in the AD brain 







Inhibiting thrombin: Implications for therapeutic intervention in AD.  
Increasing evidence supports a chronic procoagulant state in AD, highlighting 
a possible pathogenic role for thrombin in this disease. A number of studies in both 
human populations and animal models utilizing anticoagulant therapies support the 
notion that abnormalities of coagulation may promote AD pathology. Treatment of 
transgenic AD mice with enoxaparin, a low molecular weight heparin, reduces 
plaques and Aβ accumulation (Bergamaschini et al., 2004) and improves spatial 
memory (Timmer et al., 2010). As previously stated, TgCRND8 AD mice on long-term 
dabigatran administration also showed significant improvement in AD pathology 
(Cortes-Canteli et al., 2019).   
Earlier human studies showed improved cognition in dementia patients 
receiving the anticoagulant warfarin compared to untreated patients (Puccio et al., 
2009). Results from these older studies in human patients hinted at a connection 
between dementia and coagulation abnormalities, but these data were not rigorously 
pursued. A more recent community-based study found that use of the thrombin 
inhibitor dabigatran was associated with a lower risk of new-onset dementia (Jacobs 
et al., 2016). An epidemiological study on atrial fibrillation (AF) patients shows 
increased thrombin generation and fibrin turnover in subjects with AF and dementia 
compared to those without dementia, and that long-term warfarin treatment appears 
to be protective against dementia (Barber et al., 2004; Madhavan et al., 2018).  
The evidence supporting a direct connection between AF and dementia 
suggests the possibility that anticoagulant therapy for AF may reduce the incidence of 
dementia in this population, and results obtained in a number of recent population-
based studies suggest that this is indeed the case (Ding et al., 2018; Field et al., 






have found that all anticoagulants provide a level of protection (e.g. (Friberg & 
Rosenqvist, 2018)), most studies report that the direct oral anticoagulants (DOACs) 
that target thrombin are particularly efficacious (N. Chen et al., 2018; Cheng et al., 
2018; Jacobs et al., 2016). It is tempting to conclude that DOACs reduce the risk of 
AF-related dementia by decreasing the incidence of thrombotic and/or embolic 
events, but this scenario may be overly simplistic. While there is clear evidence that 
AF is associated with an increased risk of ischemic stroke (Glotzer & Ziegler, 2015), 
an ambitious meta-analysis of twenty-one studies found that the association between 
AF and dementia was not always dependent on the presence of clinical stroke 
(Kalantarian et al., 2013), raising questions regarding the mechanisms underlying this 
association (Chopard et al., 2018). Dietzel and collaborators have postulated that AF 
initiates and perpetuates an increase in systemic inflammation that may lead to 
dementia, noting recent evidence that AF is associated with increased levels of C-
reactive protein (CRP), IL-2, IL-6, IL-8, TNF-α, and other inflammatory cytokines 
(Dietzel et al., 2018). It is probable that thrombin is a key mediator of this 
inflammatory state, as it is for the inflammation that accompanies AD dementia. 
Furthermore, the utility of DOACs in the reduction of AF-related dementia is at least 
partially due to the ability of these agents to inhibit thrombin’s PAR-mediated 
inflammatory actions.  
It is therefore possible to interrupt the inflammatory cascade that contributes 
to AD by utilizing DOACs to inhibit thrombin. There is as yet no direct evidence that 
this approach will be useful in humans, but an open-label study of a hirudin (natural 
antithrombin anticoagulant) compound in 84 patients with mild-to-moderate AD found 






donepezil alone, suggesting that direct thrombin inhibition may indeed be an effective 
strategy for treating this neurodegenerative disease (Li et al., 2012).  
Although the use of any anticoagulant raises the possibility of unwanted 
bleeding, several studies have shown the safety and efficacy of dabigatran. 
Dabigatran does not interact with food, has minimal drug-drug interactions, and has a 
low risk of intracranial bleeding. A study documented that chronic use (over 30 
months) of dabigatran in patients with an average age of 71.4±8.6 had minimal side 
effects, supporting the efficacy and safety of this drug in an elderly population 
(Jacobs et al., 2016). Although not without caveats, a body of data implicating 
thrombin in AD pathogenesis and the relative safety of dabigatran suggests a pilot 








The urgent need for disease-modifying drugs in AD demands new thinking 
about disease pathogenesis and an exploration of novel drug targets. A large, and 
growing, body of literature implicates vascular pathology and vascular risk factors in 
the development of AD, but the specific mechanisms whereby these factors 
contribute to injury in the AD brain have not yet been clearly defined. It is time for 
“outside-the-box” thinking about how vascular risk factors, such as atherosclerosis 
and diabetes, as well as the coagulation and inflammatory pathways interact to 
promote increased AD risk. The evidence summarized here suggests that thrombin is 
a convergence point for AD risk factors and as such that thrombin-based therapeutics 
may therefore target multiple points of AD pathology, including neurodegeneration, 
vascular activation and neuroinflammation. Next generation AD therapeutics should 
not focus on single-target drugs but rather employ a broader, combinatorial approach. 
We propose that thrombin inhibitors be considered as potential contributors to the 
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Background. Proteins that regulate the coagulation cascade, including thrombin, are 
elevated in the brains of Alzheimer’s disease (AD) patients. Studies using amyloid-
based AD transgenic mice models have also implicated thrombin as a protein of 
interest. Although thrombin accumulation is co-localized with tau aggregation, the role 
of thrombin in tau-based animal models has not been explored.  
Objective. The current study examined how inhibiting thrombin could alter oxidative 
stress, inflammation, and tau-related proteins in the Tg4510 mouse, a tau-based 
model of AD. 
Methods. 15-month-old Tg4510 mice were treated with the direct thrombin inhibitor 
dabigatran etexilate or vehicle for 7 days. Brains were collected, and western blot and 
data-independent proteomics using mass spectrometry with SWATH-MS acquisition 
performed to evaluate proteins related to coagulation, oxidative stress, intracellular 
signaling, and tau-pathology.  
Results. Dabigatran treatment reduced thrombin and thrombin-related proteins in 
Tg4510 mice. Dabigatran also reduced indicators of oxidative stress, including iNOS 
and NOX4, and increased antioxidant proteins, SOD1 and SOD2. Dabigatran also 
reduced phosphorylation of tau species (S396, S416). Additionally, dabigatran 
treatment increased expression of several signaling proteins related to cell survival 
and synaptic function.  
Conclusion. Increasing evidence supports a chronic procoagulant state in AD, 
highlighting a possible pathogenic role for thrombin. Our data demonstrate that 
inhibiting thrombin produces alterations in the expression of proteins involved in 






thrombin-mediated signaling mechanisms in the brain affect multiple pathways 
relevant for AD and that thrombin inhibitors could play a role in a drug treatment 
regimen for AD.  







Cardiovascular disease and cardiovascular risk factors are strongly 
associated with an increased risk of developing dementia, particularly Alzheimer’s 
disease (AD). Hypertension, diabetes, atherosclerosis, and hypoxia are all linked to 
an increased risk of developing AD [1-5]. While the connection between 
cardiovascular risk factors and AD is well documented, the mechanisms whereby 
these risk factors predispose the brain to the development of AD have not been 
delineated. It is likely that one, or more, pathological mediators involved in the 
progression of cardiovascular diseases contributes to the pathology of AD. The 
multifunctional protein thrombin is implicated in the development of atherosclerosis 
and diabetes, and more recently suggested as a novel mediator in AD [6-10].  
Thrombin is a pleiotropic enzyme that triggers a large and diverse number of 
cellular events through receptor-mediated activation of protease-activated receptors 
(PARs) [11]. Recently, several laboratories have provided evidence that proteins that 
regulate the coagulation cascade, including thrombin, also propagate oxidative stress 
and neuroinflammation, invariant features of neurodegenerative diseases [12-14]. 
Thrombin is a potent mediator of oxidative stress and inflammation in a variety of cell 
types and has been increasingly implicated in pathologic processes in the brain. In 
this regard, thrombin has been shown to increase NADPH-dependent superoxide 
anion and hydrogen peroxide production, as well as to injure neurons via microglial 
release of nitric oxide [15, 16].  
Thrombin also appears to play a role in hypoxia-mediated increases in 
oxidative stress. Cerebral hypoperfusion, leading to hypoxia, has been implicated as 
an important underlying factor that promotes dementia [5, 17]. Exposure of brain 






(ROS) generation and pro-inflammatory gene expression [18, 19]. Treatment of 
cultured brain endothelial cells with the thrombin inhibitor dabigatran reduces 
hypoxia-mediated increase in ROS and inflammatory proteins, suggesting that 
thrombin may mediate the noxious downstream effects of hypoxic injury [20]. In a 
primarily amyloid-based AD mouse model (3xTgAD), we have previously shown that 
administration of the thrombin inhibitor dabigatran significantly decreases expression 
of ROS and inflammatory proteins in these mice [20].  
Increasing evidence suggests that, in addition to oxidative stress, thrombin is 
linked to several pathological pathways that are relevant for AD. Thrombin is 
expressed in AD-derived brain microvessels but not in the microvasculature of 
vessels from control-derived brains [21]. The thrombin inhibitor protease nexin-1 is 
reduced in the perivascular space in AD, supporting the idea that vascular-derived 
thrombin is increased in this disease [22]. Levels of both thrombin and the thrombin 
receptor PAR-1 are elevated in AD [23, 24]. Thrombin is also associated with AD-
related hallmarks in the brain, including amyloid and apolipoprotein E [25-29]. 
Thrombin can affect cellular secretion of amyloid-β precursor protein (AβPP) and 
could contribute to altered processing of AβPP into fragments that are found in 
amyloid plaques of AD brains [27, 28, 30]. Additionally, intracerebral administration of 
thrombin to rodents increases apolipoprotein E levels in the hippocampus and results 
in neuronal injury and cognitive deficits [31]. The 22 kDa N-terminal thrombin-
cleavage fragment of apolipoprotein E is highly neurotoxic and could contribute to 
apolipoprotein E-associated AD pathology [32]. 
There is evidence that thrombin may also be relevant to tau-related 
processes. Thrombin accumulation has been identified in neurofibrillary tangles, and 






hippocampal degeneration [25, 33]. What role thrombin may play as a pathological 
mediator in a tau-based AD model has not yet been explored. Currently, several 
tauopathy animal models are being used to study AD. One such model is the Tg4510, 
which overexpresses human tau with a P301L mutation at 13:1 versus murine tau 
[34]. These mice exhibit profound tau pathology and neuronal loss in the 
hippocampus and cortex, as well as cognitive deficits and metabolic changes. The 
pathology starts early at about 2 to 4 months of age and progresses with age [34, 35]. 
The pathological features, including tau hyperphosphorylation and synapse loss, are 
more pronounced in females than males [36]. Additionally, the Tg4510 mouse model 
displays blood vessel abnormalities accompanied by alterations in oxidative and 
inflammatory markers [37].  
Data linking thrombin to oxidative and inflammatory stress as well as AD-
related pathology suggest that thrombin could be a target for therapeutic intervention 
in this disease. Our previous demonstration in the 3xTgAD mouse that inhibiting 
thrombin reduces oxidative stress and inflammatory markers supports this idea. The 
objective of the current study is to investigate the potential therapeutic benefits of 
inhibiting thrombin in a tau-based animal model of AD. Here we explore the effects of 
short-term treatment with direct thrombin inhibitor, dabigatran etexilate, in aged 
Tg4510 mice. It is our hypothesis that inhibiting thrombin will reduce oxidative stress 
and inflammation-related indicators corresponding to an overall reduction in tau-







Materials and Methods 
Animals and Treatment 
Female transgenic Tg4510 AD mice (PF/CamKII-tTA Tg 129 x tetO-
MAPT(P301L) Tg (TG2510 TG/TG)) overexpressing human mutant tau (P301L) and 
background matched controls (PF/CamKII-tTA Tg 129 x tetO-MAPT(P301L) Tg-3 
(TG2510 WT/WT)) were a kind gift from MindImmune Therapeutics, Inc. originally 
obtained from Charles River (Wilmington, MA, USA). Mice were maintained on 
normal chow (ENVIGO 2020X, Huntingdon, UK) with water available ad libitum. At 15 
months of age, mice were treated via oral gavage with vehicle (2.5% DMSO, 2.5% 
koliphor EL, 90% diH2O) or dabigatran etexilate (100 mg/kg in uniform suspension, 
Cayman Pharm, Ann Arbor, MI) daily for 7 days. After 7 days, mice were deeply 
anesthetized with ketamine (80 mg/kg) and xylazine (10 mg/kg) administered I.P. and 
euthanized. All animal procedures were performed in accordance with NIH “Guide for 
the Care and Use of Laboratory Animals” and University of Rhode Island Institutional 
Animal Care and Use Committee (IACUC) guidelines.  
Western blot 
Whole brains minus the cerebellum, were homogenized by sonication 
(Branson SX150 Sonifier ®, Branson Ultrasonics, Danbury, CT) in 1X phosphate 
buffered saline (PBS) with protease inhibitors. Samples containing 25 g total protein 
were resolved in 4-20% poly-acrylamide gel and transferred to nitrocellulose 
membrane. Membranes were blocked using antibody-specific concentration of bovine 
serum albumin (BSA) or Milk in Tris-buffered saline + Tween (TBS-T). Primary 
antibodies for this study include thrombin (Abcam, MA; 1:500), fibrin (Santa Cruz, CA; 
1:250), NOX4 (Sigma, MA; 1:1,000), iNOS (Abcam, MA; 1:250), SOD1 (Abcam, MA; 






(GeneTex, CA; 1:1,000), and β-Actin (Santa Cruz, CA; 1:10,000). Tau and p-tau 
species were detected using phosphor-tau family antibody sampler kit (Cell Signaling, 
MA; 1:500). Bound antibody was detected with infrared secondary antibodies (Li-
COR Biosciences, Lincoln, NE). Membranes were imaged using LiCor Odyssey (LI-
COR Biosciences, Lincoln, NE), and quantification was done in ImageJ. Values for 
each protein were normalized to β-actin loading control on the same blot.  
Pressure cycling technology based protein digestion  
Whole brain homogenates were further digested using pressure cycling 
technology (PCT) for LC-MS/MS SWATH acquisition following the method by Jamwal 
et al., 2017 with slight modifications [38]. Each sample, containing 500 g of protein, 
was spiked with 2 ng of BSA. Samples were then incubated with dithiothreitol (100 
mM) at 90C for 15 min, with shaking. Iodoacetamide (200 mM) was added and 
samples were incubated at room temp in the dark for 30 min. Protein was then 
precipitated by using the ice-cold chloroform, methanol and water method (1:2:1) 
followed by centrifugation at 13,400 xG for 5 min at 10C. The protein pellet was 
rinsed with methanol and resuspended in 3% w/v sodium deoxycholate (DOC) in 50 
mM ammonium bicarbonate. Samples were placed in MicroTubes (Pressure 
BioSciences Inc, South Easton, MA) with trypsin at a 1:20 ratio of trypsin:protein. 
Digestion was performed at 55C for 75 cycles (50 sec at 35kpsi, 10 sec at ambient 
pressure) in a Barocycler NEP2320-45k (Pressure BioSciences Inc). A second 
digestion was performed by adding fresh trypsin at the same ratio and running the 
barocycler for an additional 60 cycles. Samples were then transferred to 
microcentrifuge tubes where digestion was stopped, and DOC was precipitated by 
the addition of formic acid in acetonitrile at a final percentage of 0.5%. Samples were 






Data independent proteomics using Mass Spectrometry with SWATH-MS Acquisition 
Mass spectrometry was performed as previously described with minor 
modifications [38]. Samples were analyzed on a SCIEX TripleTOF® 5600 mass 
spectrometer using a DuoSpray™ ion source (SCIEX, Framingham, MA) coupled to 
an Acquity HClass UHPLC system (Waters Corp., Milford, MA). Separation was 
achieved on an Acquity UPLC Peptide BEH C18 column (2.1 x 150 mm, 300 Å, 1.7 
µm) with an Acquity VanGuard pre-column (2.1 x 5 mm, 300 Å, 1.7 µm). The column 
temperature was set to 50˚C and the autosampler was set to 10˚C. A linear gradient 
was used with a flow rate of 100 µL/min for 90 min. Mobile phase A consisted of 
99.9% acetonitrile and 0.1% formic acid. Mobile phase B consisted of 99.9% water 
and 0.1% formic acid. The gradient was as follows: 98% A from 0 to 5 min, 98% to 
75% from 5 to 55 min, 75% to 50% A from 55 to 60 min, 50% to 20% from 60 to 70 
min. Mobile phase A was held at 20% from 70 to 75 min and returned to 98% A at 80 
min. The column was held at 98% A for 10 min to equilibrate prior to the next sample. 
A mixture of trypsin-digested β-galactosidase peptides was used between every 8 
samples to calibrate masses and monitor the TOF detector. 
Positive ionization mode was used for data dependent acquisition. The mass 
spectrometer parameters are as follows: gas 1, gas 2, curtain gas, temperature and 
ion spray voltage floating were 55 psi, 60 psi, 25 psi, 450˚C, 5500 V, Respectively. 
Declustering potential was 10, collision energy 10 and collision energy spread 15. For 
data acquisition, a maximum of 50 candidate ions were monitored for each survey 
scan. All ions had a charge state from 2 to 4. A range of m/z 300-1250 was used for 
exclusion criteria and all ions that had an intensity greater than 25 cps were chosen 
for MS/MS analysis. The temperature was set at 450˚C and the total cycle time was 






For SWATH analysis, all parameters were the same as above except for the 
following: Seventy SWATH windows per cycle were collected over m/z 400-1100 with 
each window size being m/z 10 and TOF masses were collected from m/z 300 to 
1500. 
Mass Spectrometry Data Analysis  
LC-MS/MS SWATH data were used to generate spectral libraries through 
ProteinPilot (SCIEX, Framingham, MA). Proteins of interest were identified and 
investigated. FASTA files were downloaded from UniProt [39] and imported into 
Skyline (MacCoss Lab, University of Washington). In Skyline, at least 3 transitions 
were selected per peptide, and at least 3 peptides per protein were chosen. Once 
data were analyzed, the MPPreport (MacCoss Lab, University of Washington) was 
generated and exported to excel. In excel, transitions were averaged, and the sum of 
each peptide was calculated to yield the total area under the curve representative of 
each protein. These were then standardized to internal standard, BSA.  
Statistical analysis 
Data from each experiment are expressed as mean +/- standard error (SEM), 
unless otherwise indicated. All tests were performed in GraphPad prism. Analysis 
was done by unpaired, one-tail t-test. Statistical significance was determined at 








Dabigatran treatment reduces expression of coagulation-related proteins in Tg4510 
mouse brain 
The effect of short-term (one week) treatment of Tg4510 mice with dabigatran 
on the expression of coagulation-related proteins, prothrombin and fibrin, was 
evaluated by western blot (Fig. 1A). Levels of both prothrombin and fibrin were 
significantly (p<0.01, p<0.001, respectively) elevated in Tg4510 mice compared to 
levels expressed by wild-type mice (Fig. 1B). Dabigatran treatment of Tg4510 mice 
significantly (p<0.05) reduced prothrombin level by 46.7% compared to levels 
observed in untreated Tg4510 mice (Fig. 1B). Similarly, inhibiting thrombin with 
dabigatran significantly (p<0.05) reduced fibrin expression in the Tg4510 animals to 
essentially the level demonstrated by wild-type mice (Fig. 1C). 
Expression of oxidative stress-related proteins in Tg4510 mouse brains is reduced by 
dabigatran   
Inducible nitric oxide synthase (iNOS) and NADPH oxidase 4 (NOX4) are 
enzymes involved in the generation of oxidative stress by catalyzing the production of 
NOS and ROS. The expression of both enzymes was evaluated by western blot (Fig. 
2A). The expression of iNOS was significantly (p<0.01) elevated in Tg4510 mice 
compared to wild-type, and treatment of Tg4510 mice significantly (p<0.05) reduced 
expression by 17.4% (Fig. 2B). Dabigatran treatment also significantly (p<0.01) 
reduced NOX4 expression by 24.7% compared to untreated Tg4510 mice (Fig. 2C).  
Dabigatran treatment increases expression of antioxidant proteins in Tg4510 mouse 
brains 
To more fully determine the oxidative environment in the Tg4510 brain the 






superoxide dismutase 2 (SOD2) was evaluated by western blot (Fig. 3A).The 
expression of both antioxidant proteins did not significantly differ between Tg4510 
and wild-type mice. However, Tg4510 mice treated with dabigatran showed 
significantly increased expression of both SOD1 (34.2%, p<0.01) (Fig. 3B) and SOD2 
(20.7%, p<0.05) (Fig. 3C).  
Dabigatran treatment does not alter expression of astrocytic or microglial activation-
associated proteins    
Glial fibrillary acidic protein (GFAP) and ionized calcium binding adaptor 
molecule 1 (IBA1) are markers of activated astrocytes and microglia, respectively. 
The expression of these markers in brain homogenates was evaluated by western 
blot (Fig. 4A). Both GFAP and IBA1 were significantly (p<0.001) elevated in Tg4510 
as compared to wild type-mice (Fig. 4). Treatment with dabigatran did not alter GFAP 
expression in Tg4510 mice (Fig. 4B). In contrast, dabigatran did lower Iba1 
expression, but this reduction was not significant (Fig. 4C).   
Treatment of Tg4510 mice with dabigatran diminishes levels of phosphorylated tau 
species  
Total tau and phosphorylated forms of tau S396 and S416 were evaluated by 
western blot (Fig. 5). Tg4510 mice expressed 75.9% more total tau than wild-type 
mice (p<0.001). Treatment of Tg4510 mice with dabigatran lowered total tau (22.1%) 
compared to untreated Tg4510 mice, but this reduction was not significant (Fig. 5A). 
The expression of both phosphorylated tau species S396 and S416 were significantly 
(p<0.001) elevated in Tg4510 mice compared to levels in wild-type mice. Treatment 
of Tg4510 mice with dabigatran significantly (p<0.05) lowered levels of both S396 






Proteomic expression differences between wild-type mice and Tg4510 mice are 
detected by LC-MS/MS SWATH analysis  
LC-MS/MS SWATH analysis was undertaken based on proteins relevant for 
AD-related pathological processes as well as thrombin/dabigatran-related 
mechanisms including proteins involved in the coagulation cascade, AD, inflammation 
and cell signaling. Protein sequences were obtained from the UniProt database and 
results from LC-MS/MS with SWATH acquisition analyzed in Skyline, an open source 
software for targeted proteomics (Table 1).  
Significant differences in protein expression between wild-type and Tg4510 
mice were identified and visualized with a volcano plot (Fig. 6A). Specific proteins 
within relevant functional categories that display significant differences between wild-
type mice and Tg4510 mice are shown in Figure 6B-C. Within the coagulation 
cascade classification, significant differences were detected in FIBB and THRB (Fig. 
6B). Differences were also seen in proteins related to inflammation (ICAM5, GFAP) 
and cellular signaling (RACK1) (Fig. 6B). AD-related proteins that demonstrated 
significant differences between wild-type mice and Tg4510 animals were ApoE, 
BACE1, TAU (Human), TAU (Mouse), TAU (total), G6PD1, HPCA, KCC2A, and VIME 
(Fig. 6C).  
Treatment of Tg4510 mice with dabigatran causes differences in protein expression 
as delineated by volcano and box plots  
Significant differences in AD, coagulation, inflammation, and signaling-related 
protein expression between Tg4510 mice and Tg4510 mice that were treated with 
dabigatran were identified and visualized with a volcano plot (Fig. 7A). Dabigatran 
treatment significantly increased proteins related to both inflammation and 






significantly increased (p<0.05) the levels in a number of cell signaling-related 
proteins, including DYN1, MP2K2, MP2K1, MK08, and KPCB (Fig. 7B) as well as AD-







Increasing evidence has shown that thrombin, and thrombin-related proteins 
of the coagulation cascade such as fibrin, are elevated in the brains of AD patients 
[22, 25-29, 40-42]. Furthermore, studies using amyloid-based AD transgenic mice 
models have also implicated thrombin as a protein of interest [20]. Although thrombin 
accumulation is co-localized with tau aggregation [25, 26], thrombin’s potential role in 
tau-based animal models has not been explored. In the current study we examined 
how inhibiting thrombin could alter tau-related pathologic processes.   
Our data show that efficacy of treatment with a direct thrombin inhibitor, 
dabigatran, significantly affects several AD-related pathological processes in the tau-
based Tg4510 mouse. As expected, the drug treatment reduces thrombin and 
proteins increased by thrombin activity (prothrombin, fibrin) in Tg4510 mice. 
Additionally, mass spec analysis found that dabigatran significantly increased levels 
of antithrombin III (ANT3). Antithrombin binds to thrombin and reduces its catalytic 
activity [43]. These findings indicate that dabigatran treatment effectively decreases 
thrombin levels and activity. Dabigatran treatment also produced alterations in the 
expression of proteins involved in oxidative stress, inflammation, and tau-related 
pathology. These results suggest that thrombin-mediated signaling mechanisms in 
the brain affect multiple pathways relevant for AD.  
Thrombin’s pro-inflammatory effects throughout the body, including in the 
brain, are largely mediated through the signaling of its receptors, protease-activated 
receptors (PARs) 1, 3, and 4. PARs represent a unique family of G-protein coupled 
receptors that are activated by a self-ligand [11]. PARs have been found in a number 
of cell types in the periphery and the brain, including endothelial cells, neurons, 






initiates a variety of intracellular signaling. Activation of PAR1 activates the mitogen-
activated protein kinase (MAPK) pathway, among others, which can lead to cell 
growth, proliferation, or migration [44].  
Activation of PAR1 can trigger MAPK signaling cascade, an interactive 
network of sequentially activated protein kinases that modulates a diverse array of 
cellular responses driving both physiologic (growth, survival) and pathologic 
(inflammation, apoptosis) processes [44, 45]. A large literature implicates 
dysfunctional MAPK in neurodegenerative diseases, especially AD. p38 MAPK has 
been shown to increase transcription of inflammatory genes and play a role in 
phosphorylation of tau [46, 47]. In this current study LC-MS/MS SWATH analysis 
revealed that the MAPK-related proteins MP2K1, MP2K2, and MK08 were 
significantly elevated in the brains of Tg4510 mice receiving dabigatran treatment, 
compared to untreated Tg4510 mice. In contrast to p38MAPK, MP2K1 and MP2K2, 
also known as MEK1 and MEK2, are kinases responsible for the activation of the 
ERK signaling pathway; ERK-mediated signaling is generally thought to regulate 
mechanisms of cell growth, differentiation, and survival [45, 48, 49]. There is also 
some evidence that this kinase pathway may protect against amyloid-β (Aβ)-induced 
toxicity [49, 50]. This finding suggest alternative, protective cleavage and activation of 
PAR1 in response to thrombin inhibition, possibly by activated protein C (APC), or 
another anti-coagulant mediator.  
Treatment of Tg4510 mice with dabigatran also increased expression of MK08 
(JNK1). The JNK subfamily is encoded by three separate but related genes: jnk1, 
jnk2, and jnk3, giving rise to at least ten distinct splice variants [51]. The JNKs appear 
to be involved in both neuronal degeneration and regeneration [51]. Although JNK 






tangles, it is also hypothesized to play a beneficial role in autophagy [52]. In the 
current study, it is interesting to note that dabigatran also increases dynamin-1 
(DYN1). This protein has been shown to be essential for synaptic vesicle recycling 
and, hence, for memory formation and information processing [53]. Published studies 
have shown that Aβ oligomers decrease dynamin-1 and generate toxic tau fragments 
in cultured hippocampal neurons [54]. It is unclear how to interpret the increase in 
both MK08 and DYN1 caused by dabigatran, but the relationship of both of these to 
autophagy and organelle recycling suggests these pathways should be further 
explored in light of the literature showing that autophagosome-lysosomal degradation 
is impaired and AD [55]. Finally, dabigatran treatment caused an increase in the level 
of PKC-β (KPCB). This kinase has been implicated as critical enzyme in learning and 
memory function as decreased levels of endogenous PKC-β have been associated 
with impaired spatial learning and memory [56]. This elevation of PKC-β is consistent 
with the increase we show in DYN1, a protein also functionally linked to information 
processing, and suggests that future long-term studies probing the cognitive effects of 
dabigatran in this AD model are warranted. It should be noted that a recent study in 
the TgCRND8 transgenic AD mice showed that treatment with dabigatran for one 
year improved spatial memory deficits [57].  
Thrombin activation of PARs contributes to oxidative stress and inflammation 
in both the periphery and brain. Oxidative stress resulting from generation of high 
levels of ROS in AD is consistently associated with neuron injury, Aβ accumulation, 
and tau phosphorylation [46, 58]. While a meditator of several physiologic functions, 
nitric oxide (NO) is also mediator of oxidative stress in the brain when continuously 
produced [46]. NO interacts with ROS leading to the formation of 






ultimately causing cellular death. Our laboratory and others have documented an 
increase in NO and iNOS in AD models [59, 60]. Here we show that iNOS is elevated 
in the Tg4510 mice and that treatment with dabigatran significantly reduces the 
expression of iNOS. Another source of noxious ROS in the brain is NADPH oxidase 
(NOX). NOX are a family of enzymes that directly regulate ROS production [61]. 
There is growing evidence that the isoforms NOX1, NOX2, and NOX4 are 
upregulated in a variety of neurodegenerative disease. Although it is unclear why 
NOX4 levels were comparable between wild-type mice and Tg4510, dabigatran was 
still able to lower NOX4 expression in Tg4510 mice. These findings likely indicate an 
overall reduction in oxidative stress in the Tg4510 mice, but follow-up examination of 
enzyme activity would be necessary to confirm a reduction in pathogenic activity.  
The SOD enzyme is responsible for reducing oxidative stress by converting 
superoxide radicals to hydrogen peroxide and oxygen [62]. Our data show that 
expression of both SOD1 and SOD2 is comparable between expressed wild-type and 
Tg4510 mice. Diminished levels of these enzymes are often associated with 
instances of ROS-mediated cellular damage [63]. Interestingly, high levels of SOD 
are also observed in instances of oxidative stress as metabolic disturbances lead to 
upregulation of cellular antioxidant capacity to maintain ROS levels below a toxic 
threshold [64]. Increasing endogenous SOD levels and/or activity has been a target of 
antioxidant intervention strategies using compounds like curcumin [65]. Here we 
show that dabigatran can significantly increase SOD1, and SOD2 levels in the tau-
mouse model. It is possible that dabigatran not only reduces oxidant stress by directly 
reducing the direct actions of thrombin, but also by increasing SOD. 
The role of dabigatran as an anti-inflammatory drug in this animal model is 






activation for astrocytes and microglia, respectively, were significantly (p<0.001) 
elevated in Tg4510 as compared to wild type-mice. Treatment with dabigatran did not 
significantly affect their expression. This is congruent with another study that found no 
significant difference in GFAP or IBA1 following dabigatran treatment in Tg2576 [66], 
but it is in contrast to other studies that reported treatment of the 5xFAD mouse with 
dabigatran diminished expression of both GFAP and IBA1 [67]. This divergence in 
results may in part reflect length of treatment, as dabigatran dosing was much longer 
(4 weeks) in the 5xFAD mice compared to our short-term 7-day timeframe. Also, the 
animals in that study were young (8-week-old) and our mice were in late-stage (15 
months old) disease state. Another observation we document herein is that COX-2 is 
elevated in response to dabigatran. Although COX-2 is primarily identified as a 
noxious mediator of neuroinflammation, failure of clinical trials with selective COX-2 
inhibitors and NSAIDs suggest that the involvement of COX-2 in AD pathology is 
more complex [68]. In that regard, COX-2 expression in AD neurons is associated 
with aberrant expression of cell cycle proteins which could suggest involvement of 
COX-2 in regenerative pathways [68]. Future studies are needed to further the role of 
COX-2 in neuronal viability.  
Total tau and related phosphorylated (S396, S416) tau species were 
significantly increased in transgenic mice compared to wild type, as was expected. 
Dabigatran treatment slightly reduced expression of total tau and significantly 
decreased S396, S416. S396 phosphorylation is found early in the disease course of 
AD [69, 70] and is related to destabilization of microtubules [71, 72]. S396 is also 
linked with abnormal truncation of the tau protein, indicating altered functionality [69]. 
Phosphorylation at S416 by CamKII is largely found within the neuronal soma, rather 






promotion of AD-related cell death [73, 74]. Together, our findings indicate that 
dabigatran etexilate treatment may reduce AD-related tau dysfunction through altered 
phosphorylation, particularly decreased phosphorylation at S396 and S416.  
To further explore AD-related pathology, we performed LC-MS/MS SWATH 
analysis on a variety of previously identified AD and tau-related proteins. Here, 
ANS1B, NCKP1, SV2B and SYGP were significantly increased with dabigatran 
treatment, compared to Tg-Vehicle. In a previous report analyzing tau pathology in 
human AD brains, these proteins were found to be significantly downregulated in late-
stage AD [75]. ANS1B (Ankyrin repeat and sterile alpha motif domain-containing 
protein 1B) is a scaffold protein localized to the post-synaptic density. It has an 
identified role in facilitating long-term potentiation (LTP). Additionally, ANS1B has 
been found to regulate endothelial barrier function and permeability; ANS1B 
knockdown produced significantly increased endothelial barrier permeability in vitro 
[76]. A significant increase in ANS1B may therefore suggest improved endothelial 
barrier function following dabigatran treatment. Alterations in blood-brain barrier 
(BBB) function and permeability have been identified in AD pathology [77-79], further 
highlighting the possible therapeutic benefits of dabigatran treatment. Significant 
increases in SV2B (synaptic vesicle glycoprotein 2B) and SYGP1 (Ras/RTP GTPase 
activating protein), further highlight the possible protective benefits of dabigatran 
treatment. SV2B is a mediator of synaptic vesicle transport and exocytosis, and an 
increase in SV2B expression has previously been tied to behavioral improvements in 
mice following environmental enrichment [80]. SYGP1 regulates the trafficking of α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors to the cell 
membrane, and therefore plays a critical role in regulating neuronal plasticity, 






dabigatran treatment may increase neuronal function at the synapse and promote 
improved plasticity and learning potential.  
Dabigatran may impact oxidative and inflammatory processes by mechanisms 
other than direct inhibition of thrombin-receptor-mediated pathways. Thrombin activity 
drives the formation of fibrin, and fibrin has been identified as a potential pathological 
mediator in AD [83]. Higher levels of fibrin have been identified in the AD brain 
compared to healthy controls [42], and fibrin accumulation in AD, similar to thrombin, 
has been linked with increases in inflammation and oxidative stress, as well as 
alterations in both amyloid and tau pathology [83]. Our findings showed a decrease in 
fibrin expression as a result of dabigatran treatment. It is likely that the beneficial 
effects of dabigatran treatment, including decreases in oxidative stress-related and 
inflammatory proteins, are attributable to both decreased fibrin accumulation as well 
as reduced thrombin receptor-mediated activity. 
Thrombin inhibition may also indirectly promote anti-oxidative and anti-
inflammatory processes through increased activity of endogenous anti-coagulants. 
Anti-coagulant proteins, such as activated protein C (APC), act in opposition to 
thrombin [84]. For example, activation of PAR1 by thrombin induces proinflammatory 
signaling responses whereas the activation of the same receptor by APC elicits anti-
inflammatory responses in cultured human umbilical vein endothelial cells (HUVECs) 
[85, 86]. Several studies have shown anti-inflammatory effects of APC-like ligands 
mediated through PAR signaling [87]. Just as reduced thrombin activity may result in 
reduced fibrin accumulation and therefore reduced inflammation, reduced levels and 
activity of thrombin following dabigatran treatment may allow for APC and other anti-







Increasing evidence supports a chronic procoagulant state in AD, highlighting 
a possible pathogenic role for thrombin in this disease. Studies in both animal models 
and human populations utilizing anticoagulant therapies support the notion that 
mediators of the coagulation cascade may promote AD pathology. A recent study 
showed that treatment of TgCRND8 transgenic AD mice with dabigatran improved 
spatial memory deficits, reduced neuroinflammation, and amyloid plaque formation 
[57]. An open-label study of a hirudin (natural antithrombin anticoagulant) compound 
in 84 patients with mild-to-moderate AD found that hirudin plus donepezil reduced the 
rate of cognitive decline compared to donepezil alone, suggesting that direct thrombin 
inhibition may indeed be an effective strategy for treating this neurodegenerative 
disease [88]. Indirect thrombin inhibitors, such as warfarin, exert anti-inflammatory 
and neuroprotective effects in models of AD [89]. However, direct thrombin inhibition 
with dabigatran may be a safer treatment option, with a reduced risk of intracerebral 
hemorrhage [90]. In a longitudinal, community-based study use of dabigatran was 
associated with a lower risk of new-onset dementia compared to warfarin [91]. Taken 
together these studies demonstrate that targeting thrombin could be beneficial in AD 
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Table 1. List of proteins and corresponding abbreviations. Proteins of interest 
were identified, classified, and categorized based on previous literature. Proteins 
were obtained from UniProt and data obtained by LC-MS/MS with SWATH acquisition 








Figure 1. Dabigatran treatment reduces expression of coagulation-associated 
proteins in Tg4510 mouse brain. Brain homogenates from wild-type mice, Tg4510 
mice (Tg-Vehicle), and Tg4510 mice treated with dabigatran (Tg-Dabigatran) for one 
week were analyzed by western blot (A) for prothrombin (B) and fibrin (C).  Data are 
expressed as mean  SEM (n=4-6) and significance determined by t-test, *p  0.05, **p < 









Figure 2. Expression of oxidative stress-related proteins in Tg4510 mouse brains 
is reduced by dabigatran.  Brain homogenates from wild-type mice, Tg4510 mice (Tg-
Vehicle), and Tg4510 mice treated with dabigatran (Tg-Dabigatran) for one week were 
analyzed by western blot (A) for iNOS (B) and NOX4 (C). Data are expressed as mean  









Figure 3. Dabigatran treatment increases expression of antioxidant proteins in 
Tg4510 mouse brains. Brain homogenates from wild-type mice, Tg4510 mice (Tg-
Vehicle), and Tg4510 mice treated with dabigatran (Tg-Dabigatran) for one week were 
analyzed by western blot (A) for SOD1 (B) and SOD2 (C). Data are expressed as mean 








Figure 4. Dabigatran treatment does not alter expression of astrocyte or microglial 
activation-associated proteins. Brain homogenates from wild-type mice, Tg4510 mice 
(Tg-Vehicle), and Tg4510 mice treated with dabigatran (Tg-Dabigatran) for one week 
were analyzed by western blot (A) for GFAP (B) and IBA1 (C). Data are expressed as 








Figure 5. Treatment of Tg4510 mice with dabigatran diminishes levels of 
phosphorylated tau species. Brain homogenates from wild-type mice, Tg4510 mice 
(Tg-Vehicle), and Tg4510 mice treated with dabigatran (Tg-Dabigatran) for one week 
were analyzed by western blot for total tau (A) tau S396 (B) and tau S416 (C). Data are 
expressed as mean  SEM (n=4-6) and significance determined by t-test, *p  0.05, **p  









Figure 6. Proteomic expression differences between wild-type mice and Tg4510 
mice are detected by LC-MS/MS SWATH analysis. Volcano plot of data sets from 
brain homogenates of wild-type mice and Tg4510 mice (Tg-Vehicle) is shown in 
panel A. Data points are color-coded into functional categories as follows:  
Alzheimer’s Disease (blue), coagulation cascade (pink), inflammation-related (green), 
and cell signaling (grey). Non-significant differences are denoted in black (A). 
Proteins related to inflammation, cell signaling, and the coagulation cascade that 
show significant expression differences between wild-type (○) and Tg-Vehicle (□) are 
shown in B. Alzheimer’s disease-related proteins with significant expression 
differences between wild-type and Tg-Vehicle in are shown in C. Data points are 
expressed as mean +/- SEM, and statistical differences determined by multiple t-










Figure 7. Treatment of Tg4510 mice with dabigatran causes differences in 
protein expression. Volcano plot of data sets from brain homogenates of Tg4510 
mice (Tg-Vehicle) and Tg4510 mice treated with dabigatran (Tg-Dabigatran) is shown 
in panel A. Data points are color-coded into functional categories as follows:  
Alzheimer’s Disease (blue), coagulation cascade (pink), inflammation-related (green), 
and cell signaling (grey). Non-significant differences are denoted in black (A). 
Functional categories of proteins that show significant expression differences 
between Tg-Vehicle (□) and Tg-Dabigatran (∆) are shown as follows: coagulation 
cascade, inflammation-related, and cell signaling (B) and Alzheimer’s disease-related 
(C). Data points are expressed as mean +/- SEM, and statistical differences 








Alzheimer's disease (AD) is the most common form of dementia, and represents 
a growing health crisis. There is a preponderance of literature highlighting the 
relationship between cardiovascular disease and increased risk for developing AD, 
but the mechanism responsible for this risk is not well understood. Here, we explore 
the relationship between cardiovascular risk factors and AD pathology, highlighting 
possible shared pathological processes and mediators.  
 Type II diabetes mellitus (T2D) more than doubles the risk for AD, and one 
area of possible convergence is endothelial activation and endothelial-based 
inflammation. Here, diabetes-like hyperglycemic conditions injure brain endothelial 
cells. In turn, this hyperglycemia-mediated endothelial cell injury induces activation of 
a pro-inflammatory microglia phenotype like that found in the AD brain. These results 
highlight the pro-inflammatory nature of cerebrovascular dysfunction, and a possible 
role for endothelial cells in the neuroinflammatory response found in AD.  
The E4 allele of the lipid transport protein apolipoprotein E4 (ApoE4) is the 
strongest known genetic risk factor for AD. In chapter two, we explore the 
mechanisms behind ApoE-associated increased AD risk. ApoE4 produced increased 
neuroinflammation and neurotoxicity in vitro, while ApoE2 was found to be 
neuroprotective. Additionally, ApoE4 produced vascular dysfunction and related 
inflammation in the brain in vivo, and these changes appeared to be heightened in 
females compared to males. 
Finally, chapter three highlights the role for the coagulation protein thrombin 
as a shared pathological mediator in cardiovascular disease and AD. An extensive 
literature review implicates thrombin as a driver of vascular activation and 






supported by the finding that pharmacological inhibition of thrombin with the direct 
thrombin inhibitor dabigatran significantly reduced oxidative stress and alleviated AD-
related pathology in a tau-based animal model of AD. These changes included 
reduced iNOS and NOX4 expression, reduced tau phosphorylation, and increased 
neurogenic signaling processes.  
 Altogether, this body of work highlights vascular dysfunction and related 
neuroinflammation as convergence points for cardiovascular disease and AD-related 
pathology, and emphasizes the role of shared pathological mediators, including ApoE 
and thrombin. Importantly, these findings give insight into the possible long-
developing mechanisms responsible for the elevated AD risk associated with 
cardiovascular disease and related risk factors, and offers new potential therapeutic 
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